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CHAPTER I 
GENERAL INTRODUCTION 
 
 Glucose is the primary energy source for the majority of animal cells. The pathways 
of glucose metabolism are complex and interconnected. The complete oxidation of glucose 
to CO2
 requires two major pathways: glycolysis and the citric acid cycle (CAC). Glycolytic 
reactions take place in the cytosol and CAC reactions are compartmentalized in the 
mitochondria. Reducing equivalents produced during glucose oxidation are used in 
oxidative phosphorylation to produce ATP, the predominant intracellular energy molecule. 
Glucose can also be produced intracellularly through both glycogenolysis and 
gluconeogenesis (GNG). Glycogenolysis produces glucose from glycogen stores. GNG 
produces glucose from many different non-carbohydrate carbon sources. Lactate, glycerol, 
and gluconeogenic amino acids can all be used to generate glucose. Many of the same 
reactions of glycolysis and CAC are used in GNG. 
In the whole animal, maintaining blood glucose homeostasis is vital to ensure that 
cellular energy needs are met. When blood glucose is high, insulin is released from the β-
cells of the pancreas. Insulin signaling activates glucose uptake and utilization throughout 
the body. Liver and muscle cells clear excess glucose and store it as glycogen. Conversely, 
when blood glucose is low, glucagon is released from the α-cells of the pancreas. Glucagon 
activates glycogenolysis and GNG in hepatocytes. During fasting, the liver is primarily 
responsible for producing glucose to maintain blood glucose homeostasis, which ensures 
cellular energy needs are continuously met throughout the body. The regulation of glucose 
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homeostasis involves whole animal metabolism and, thus, necessitates the development of 
system-level approaches.  
Glucose metabolism is carefully regulated. In addition to hormonal control, the rate 
of turnover of molecules – or flux ‒ through each step in the pathway can be regulated by 
allosteric effectors, covalent modifications, substrate cycling, or by enzyme and substrate 
availability. Despite this complexity, metabolic pathway alterations are often inferred from 
changes in enzyme expression. For many enzymes, mRNA or protein abundances do not 
correlate with flux (13, 25). Flux analysis, which combines metabolite measurements with 
mathematical modeling, provides comprehensive information on the dynamics of carbon 
flow through a metabolic network.  
Disruptions in normal glucose metabolism and homeostasis can cause or indicate 
disease. Changes in normal glucose metabolism are the hallmark of type 2 diabetes, a 
condition rising in prevalence and closely linked to the current obesity epidemic (14). In 
addition to diabetes, many cancer cells exhibit profound metabolic reprogramming. The 
Warburg effect is a common metabolic phenotype in cancer cells, whereby glycolytic flux 
and lactate production are significantly elevated in comparison to control cells (28). 
Characterizing glucose metabolism in cancer cells is used diagnostically, prognostically, 
and to evaluate treatment efficacy (28). In non-alcoholic fatty liver disease (NAFLD), 
abnormal accumulation of fatty acids in hepatocytes causes ER stress and mitochondrial 
dysfunction that alters CAC flux and induces oxidative stress (21, 45). Changes in glucose 
metabolism have been linked to many other diseases, from polycystic kidney disease (60) 
to sleep apnea (41) to Alzheimer’s disease (17, 62). Because glucose metabolism is central 
to energy homeostasis and dysfunctional in many human disease states, the development 
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of sensitive, quantitative methods to characterize glucose metabolism is of vital 
importance.  
 Isotope labeling experiments are performed to quantitatively measure flux. Stable 
isotopes, which are naturally occurring isotopes with one or more extra neutrons, are often 
utilized as labels because they are less expensive, more stable, and safer to handle than 
radioisotopes. Labeling experiments generally require a higher concentration of stable 
isotopes than radioisotopes because of the natural, baseline abundance of stable isotopes in 
the environment. However, stable isotopes provide a richer data set than radioisotopes, 
which supports flux analysis. In these studies, 2H and/or 13C-labeled substrates, are 
introduced to a system (i.e. cells in culture or a laboratory mouse). Careful measurement 
of the labeling patterns of one or more intermediates or products of the metabolic network 
allows the flux through the pathways to be quantified. For many studies, the application of 
stable isotope tracers requires the accurate analysis of the number and position (or 
positional enrichment) of isotopes on the measured products. Because accurate positional 
enrichment is required, analysis is currently constrained to nuclear magnetic resonance 
(NMR) spectroscopy. NMR equipment costs, lengthy sample analysis times, large sample 
volume requirements, and low sensitivity are significant limitations to the application of 
stable isotope tracers.  
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Figure 1.1  
Positional enrichment analysis of glucose using overlapping GC-MS fragments. Six ions – m/z 
145, 173, 259, 284, 301, and 370 – break up the parent glucose molecule into overlapping fragments 
that can be used to determine positional enrichment computationally. 
  
Gas chromatography-mass spectrometry (GC-MS) can measure the mass shifts 
expected with stable isotope labeling. However, unlike NMR, GC-MS cannot readily 
perform positional enrichment analysis. The sensitivity of GC-MS, combined with the 
lower cost and higher throughput, make it desirable for stable isotope studies. Recently, a 
novel method for evaluating positional enrichment using GC-MS was published (4). This 
proof-of-concept showed that a combination of glucose derivatization, GC-MS, and linear 
regression could be used to precisely measure the positional enrichment of 2H on tracer 
glucose standards. The chemically distinct glucose derivatives elute at different times and 
fragment into unique ions. Evaluating the mass isotopomer distribution (MID) of six 
fragment ions provides overlapping information at each carbon position of the parent 
glucose molecule (Figure 1.1). Using least-squares (LSQ) regression, the fractional 
abundance of each of the 27 possible hydrogen isotopomers of glucose can be estimated, 
and the total enrichment of 2H at each carbon position can be determined (Figure 1.2).  
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In this work, the GC-MS-based methodology was validated in biological samples 
and used to investigate biological systems. The second chapter details the validation studies 
and the creation of MATLAB-based user interface tools that improve the accessibility of 
the method. In the third chapter, the validated methodology is used to study glucose cycling 
in isolated mouse islets. Finally, in Chapter IV, the overlapping fragments are used with a 
metabolic network model to perform flux analysis in vivo.   
 
 
Figure 1.2  
Overview of GC-MS-based positional enrichment methodology. Sample glucose isotopomers 
are derivatized three ways. Each derivative is distinct in structure and mass. The derivatives elute 
at different retention times and produce different ion fragments. The overlapping ion fragments are 
used to estimate the abundance of each of the possible 27 hydrogen isotopomers of glucose.  
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CHAPTER II 
SAMPLE PROCESSING AND ANALYSIS OF GC-MS DATA 
 
 In all studies, glucose was derivatized, as described by Antoniewicz et al. (2), from 
biological samples. The three glucose derivatives were analyzed by GC-MS (Figure 1.2). 
The derivative peaks were integrated using a fixed-width, adjustable baseline algorithm (1) 
adapted into a MATLAB-based user interface. Integration produced MIDs for six ions of 
interest (Figure 1.1). The ions produced overlapping information for each carbon position 
of the parent glucose molecule. In studies shown here and in Chapter III, this overlapping 
information was used in a LSQ regression (2) to obtain positional enrichment estimates. In 
studies detailed in Chapter IV, the overlapping information was used with a network model 
to estimate metabolic fluxes. An overview of sample processing and data analysis is 
provided in Figure 2.1.  
 
Figure 2.1  
Overview of sample and data processing. Samples were collected from cell culture media or 
blood. Each sample was derivatized through three separate protocols. The samples were analyzed 
by GC-MS. Each derivative peak was integrated, and the resulting MIDs were used to perform 
positional analysis or metabolic flux analysis (MFA).  
 
Preparation of glucose derivatives 
 Low sample volume requirements are a significant advantage of the methodology, 
especially for in vivo applications. Only 50 µL of cell culture media or blood plasma is 
necessary for analysis. In these studies, samples were divided into three aliquots, and each 
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was derivatized separately to obtain di-O-isopropylidene propionate, aldonitrile 
pentapropionate, and methyloxime pentapropionate derivatives of glucose.  
Proteins were precipitated from 20 µL of sample using 300 µl of cold acetone, and 
the supernatant was decanted to a glass screw-cap culture tube. The supernatants were 
placed in a 60°C heating block and evaporated to dryness under air flow. 500 µL of a 1:46 
sulfuric acid:acetone solution was added to each tube, and the samples were incubated at 
room temperature for 60 minutes. 400 µL of 0.44 mM sodium carbonate solution was 
added to neutralize the reaction. 1 mL of saturated sodium chloride and 1 mL of ethyl 
acetate were added to each tube. The tubes were shaken vigorously to mix and incubated 
2 minutes at room temperature for phase separation. The top, organic layer was carefully 
transferred to a microcentrifuge tube using a glass Pasteur pipette. This layer was 
evaporated to dryness under air flow at room temperature. 150 µL of a 2:1 solution of 
propionic anhydride:pyridine was added to each tube, and the samples were incubated 30 
minutes at 60°C. The samples were placed in a 60°C heating block and evaporated to 
dryness. The dried samples were resuspended in 100 µl of ethyl acetate and centrifuged 10 
minutes at 14,000 rpm to pellet solid debris. The samples were then transferred to GC 
injection vials with 250 µl glass inserts for GC-MS analysis. 
For both aldonitrile and methyloxime derivatization, proteins were precipitated 
from 10 µl of sample using 300 µl of cold acetone, and the supernatants were decanted to 
microcentrifuge tubes. The supernatants were placed in a 60°C heating block and 
evaporated to dryness under air flow. 50 µL of 2 wt% hydroxylamine hydrochloride in 
pyridine solution or 2 wt% methoxyamine hydrochloride in pyridine solution was added to 
each tube for aldonitrile and methyloxime derivatization, respectively. All samples were 
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incubated 60 minutes at 90°C. 100 µL of propionic anhydride was added to each tube, and 
the samples were incubated 30 minutes at 60°C. The samples were placed in a 60°C heating 
block and evaporated to dryness under air flow.  The dried samples were resuspended in 
100 µl of ethyl acetate, centrifuged to pellet solid debris, and transferred to GC injection 
vials with 250 µl glass inserts for GC-MS analysis.  
 
GC-MS analysis 
 GC-MS analysis was performed using an Agilent 7890A gas chromatography (GC) 
System with an HP-5 ms (30 m x 0.25 mm x 0.25 μm; Agilent J&W Scientific) capillary 
column interfaced with an Agilent 5975C mass spectrometer (MS). For optimal signal-to-
noise, injection volumes were varied between 1-5 µl with purge flow times between 30-60 
seconds. Samples were injected into a 270°C injection port in splitless mode. Helium flow 
was maintained at 0.88 ml/min. For analysis of di-O-isopropylidene and aldonitrile 
derivatives, the column temperature was held at 80°C for 1 minute, ramped at 20°C/minute 
to 280°C and held for 4 minutes, then ramped at 40°C/min to 325°C. For methyloxime 
derivatives, the same oven program was used except the ramp to 280°C was 10°C/minute. 
After a 5 minute solvent delay, the MS collected data in scan mode from m/z 300 to 320 
for di-O-isopropylidene derivatives, m/z 100 to 500 for aldonitrile derivatives, and m/z 144 
to 260 for methyloxime derivatives.  
 
Integration of glucose derivative peaks 
The raw GC-MS data was converted from the proprietary ChemStation format to 
NetCDF using File Translator Pro (http://www.sisweb.com/software/csw/gcmsfile.htm). 
 9 
 
Each derivative peak was integrated using a custom MATLAB function to obtain MIDs 
for six specific ion ranges: aldonitrile - m/z 173-176, 259-263, 284-287, 370-374; 
methyloxime - m/z 145-147; di-O-isopropylidene - m/z 301-321.  
The fixed width-adjustable baseline integration algorithm proposed by 
Antoniewicz et al. (1) and adapted by the Young lab is unique in several ways. Traditional 
“peak picker” algorithms often identify peaks by finding local maxima using the first 
derivative method. This integration algorithm, however, relies on probabilities to identify 
the most likely peak. The method requires the analyst to provide accurate information on 
each metabolite of interest, similar to the information found in the NIST mass spectral 
library. Specifically, the user must input: estimated retention time; at least two main ions 
or main ion ranges; estimated relative abundance of each main ion. The algorithm first 
computes the probability that a metabolite peak is at a given time value based on the ratios 
of relative intensities of the main ions. Then, the probability that a metabolite peak is at a 
given time value is calculated based on the provided retention time. The most likely peak 
location is identified as the time value where the product of the probabilities is the greatest.  
The peak start and peak end values are calculated from the selected ion 
chromatogram (SIC) made up of the sum of the main ions. The algorithm moves down the 
summed peak until the signal is equal to the baseline times a noise multiplier. The width 
of the peak is fixed and used in the integration of each mass isotopomer SIC. Using this 
strategy, data can be collected from low abundance mass isotopomers that do not have a 
clean peak. This component of the algorithm is key for analyzing biological samples, which 
contain many metabolite peaks and significant noise. The algorithm is robust against 
common artifacts like peak tailing and shouldering.  
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The computational time required for integration by this method was significantly 
lower than for built-in MATLAB peak finding functions, including findpeaks and mspeaks. 
In addition, Antoniewicz et al. (1) and our work showed that the algorithm provided more 
accurate MIDs than other methods.   
 One collaborator of the Young lab was manually integrating each metabolite peak 
in the mass spectrometer instrument software. By eye, the middle 70% of the peak was 
estimated, and the average intensity was calculated. The location of the baseline was 
estimated, and the baseline intensity was subtracted from the average peak intensity. I 
analyzed this data using the integration algorithm described above and by MATLAB’s 
mspeaks function. To assess uncertainty, root-mean-square error (RMSE) was calculated 
by comparing the baseline MID of unlabeled metabolites in the sample to the theoretical 
MID computed from the known abundances of naturally occurring isotopes. The average 
maximum RMSE was 0.90% ± 0.10% (n=5) by the manual method. Our integration 
algorithm produced MIDs with maximum RMSE that was not significantly different 
(0.96% ± 0.13%) at a fraction of the time. mspeaks produced MIDs with significantly 
higher RMSE (1.77% ± 0.38%).    
 
Guided integration using integrate_gcms 
A disadvantage of the GC-MS-based methodology is the extensive computation 
required. To improve the accessibility of the methodology, the computational methods 
were packaged into user-friendly interface tools in the MATLAB programming 
environment. The MATLAB-based tool integrate_gcms (Figure 2.2) identifies derivative 
peaks from a user-defined method file in an automated fashion on a batch of files, while 
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allowing the user to visually check and manually refine the peak start, peak end, and 
baseline. Integration of each peak produces a spreadsheet with MIDs for each ion range 
defined in the method. This tool has been tested in the Young laboratory and in 
collaborating labs. It has proven invaluable for stable isotope studies, allowing complete 
visualization of metabolite peaks and automated integration in a single tool. A full user 
manual is included in APPENDIX A.  
 
Figure 2.2  
The integrate_gcms GUI guides a user through integration to produce MIDs.  
 
Evaluation of the accuracy of fragment measurements from biological samples 
 Plasma samples from mice were collected, and the naturally labeled blood glucose 
was derivatized and analyzed by GC-MS. The measurement error associated with each 
glucose derivative fragment was evaluated by comparing the experimental MIDs to the 
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theoretical MIDs, based on the natural abundance of stable isotopes. The maximum RMSE 
was calculated by Equation 2.1:  
𝑚𝑎𝑥 (√
∑ (𝑀𝐼𝐷𝑀 − 𝑀𝐼𝐷𝑇)2
𝑛
𝑖=1
𝑛
) (2.1) 
  
where MIDM was the measured MID, MIDT was the theoretical MID, and n was the number 
of samples. It was expected that measurement error would be higher in biological samples 
than previously reported for pristine glucose standards (≤0.3%, (4)). Indeed, in this study, 
the RMS error ranged from ~0.4-1.0% (Table 2.1).  
 
Table 2.1   
Maximum RMSE in fragment measurement from plasma samples.  
 
Fragment 
(m/z) 
Maximum RMSE 
(n=30) 
145 0.63% 
173 0.43% 
259 0.38% 
284 0.95% 
301 0.79% 
370 0.45% 
 
Naturally labeled blood glucose was derivatized, and the derivatives were analyzed by GC-MS. 
The RMSE was calculated by comparing the experimental MIDs, obtained by integration, to the 
theoretical MID.  
 
 
Positional enrichment analysis of glucose 
In studies detailed in this chapter and in Chapter III, positional enrichment analysis 
(adapted from (4)) was performed using a LSQ regression. After integration of glucose 
derivative peaks, the six measured MIDs were linearly combined into a single vector in 
MATLAB (MIDM). The theoretical MIDs expected for each of the 128 possible hydrogen 
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isotopomers of glucose were calculated based on natural isotope abundances (8) and the 
atomic formula of each fragment. Theoretical MIDs were combined into a matrix, T. 
Multiplying T by a fractional contribution matrix, x, produced a vector of MIDs (MIDC) 
expected from the x-defined mixture of hydrogen isotopomers (Equation 2.2). The LSQ 
regression minimized the difference between MIDM and MIDC by manipulating x (Equation 
2.3). The first output of the computational method is an estimation of the relative 
abundance of each hydrogen isotopomer in the sample. Multiplying this output, x, by a 
transformation matrix that defines each hydrogen isotopomer in terms of zeros, 
representing unlabeled carbons, and ones, representing labeled carbons, produces a second 
output that quantifies the total 2H enrichment at each of the six carbon positions of glucose. 
𝑀𝐼𝐷𝐶 = 𝑇 × 𝑥 (2.2) 
min ∑(𝑀𝐼𝐷𝐶 − 𝑀𝐼𝐷𝑀)
2 (2.3) 
 
 
The effect of measurement error on enrichment estimates 
The calculated RMSEs (Table 2.1) were used in simulation studies in MATLAB to 
determine the effect of measurement error on 2H enrichment estimates. 2H2O is often used 
as a gluconeogenic tracer (43). In in vivo studies, the water of fasted animal subjects is 
supplemented with 2H2O and/or a bolus of 
2H2O is administered to enrich body water to 4-
5%. Singly labeled glucose molecules (M+1 isotopomers) are produced, predominantly 
with labeling at carbons 2 and 5. To simulate a biological sample from a 2H2O study, the 
expected MIDs (MIDC) for a mixture of M+1 glucose isotopomers, with fractional 
abundances defined in x, was calculated. For each fragment, measurement error was added 
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as random noise to the MID in 10 separate trials. The LSQ regression algorithm was used 
to estimate the 2H enrichment at each carbon position. The enrichment estimates from 
MIDs without and with added measurement error were compared. With simulated 
measurement error, significant deviations from the expected values were reported. 
Significant overestimations were reported at positions 1, 3, and 6. Enrichment at carbons 
2 and 5 were underestimated (Method 1, Table 2.2).  
 
Table 2.2  
Effect of measurement error on enrichment analysis of simulated biological mixtures.  
 
 Mean Enrichment ± SEM % (n=10) 
 Expected Method 1 Method 2 Method 3 Method 4 
C1 1.5 4.1 ± 2.0 3.2 ± 1.7 2.4 ± 1.5 1.7 ± 1.1 
C2 6.0 4.3 ± 2.3 5.3 ± 2.4 4.6 ± 1.6 5.9 ± 1.1 
C3 1.5 5.2 ± 2.3 3.4 ± 1.9 3.2 ± 1.6 1.9 ± 0.9 
C4 1.5 1.8 ± 0.7 2.1 ± 1.4 1.6 ± 0.5 1.3 ± 0.8 
C5 3.0 2.6 ± 0.7 3.5 ± 1.1 2.6 ± 1.1 3.0 ± 1.2 
C6 0.5 1.5 ± 0.4 0.8 ± 0.4 0.6 ± 0.5 0.5 ± 0.4 
MIDs were simulated assuming 1.5% [1-2H]glucose,  6% [2-2H]glucose, 1.5% [3-2H]glucose, 1.5% 
[4-2H]glucose, 3% [5-2H]glucose, 0.5% [6-2H]glucose, and 86% unlabeled glucose (Expected). 
Random measurement error was added. 2H enrichment at each carbon was calculated using an 
unweighted (Method 1 and 3) or weighted (Method 2 and 4) LSQ regression. Methods 3 and 4 used 
a simplified model, reducing the number of possible hydrogen isotopomers from 128 to 8.  
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Figure 2.3 
Effect of measurement error on enrichment analysis of a simulated biological mixture. MIDs 
were simulated assuming 1.5% [1-2H]glucose,  6% [2-2H]glucose, 1.5% [3-2H]glucose, 1.5% [4-
2H]glucose, 3% [5-2H]glucose, 0.5% [6-2H]glucose, and 86% unlabeled glucose (Expected, dotted 
line). Random measurement error was added. 2H enrichment at each carbon position from carbon 
1 (C1) to carbon 6 (C6) was calculated using an unweighted (Method 1 and 3) or weighted (Method 
2 and 4) LSQ regression. Methods 3 and 4 used a simplified model, reducing the number of possible 
hydrogen isotopomers from 128 to 8. The x-axis abbreviates Methods 1-4 as M1-M4. The y-axis 
shows the average enrichment ± SEM % (n=10).  
 
 
Performing a weighted LSQ regression, where the weights for each fragment were 
set as the inverse maximum RMSE, improved the accuracy of the estimation at carbon 2 
and reduced erroneous enrichment estimations at carbons 1, 3, and 6 (Method 2, Table 2.2). 
The accuracy of the estimations was further improved by adjusting the number of possible 
hydrogen isotopomers of glucose in the model. For 2H2O labeling studies, it can be 
assumed that glucose will be unlabeled or singly labeled; the probability of double labeling 
is low. Therefore, the number of possible hydrogen isotopomers in the model was reduced 
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from 128 to 8 (unlabeled glucose and 7 M+1 isotopomers). The estimations from the 
unweighted LSQ with the simplified model showed a reduction in enrichment at carbons 1 
and 6 (Method 3, Table 2.2). With the simplified model, weighting improved the accuracy 
of the estimation at carbons 2 and 5 and further reduced erroneous estimates (Method 4, 
Table 2.2).  
The effects of measurement error were overcome by weighting the fragments and 
by making assumptions to simplify the number of active isotopomers in the model. The 
simple mixture detailed in this example would not apply to every experiment. If a 
significant accumulation of M+2 isotopomers was observed in a 2H2O study, different 
assumptions would be applied, and the model would be simplified to 29 isotopomers (M+0, 
M+1, M+2). Extensive testing of the regression algorithm showed that, with adjustments, 
it is fully capable of producing accurate estimations of complex biological mixtures.  
 
 
Automated glucose positional enrichment analysis 
A tool for automated positional enrichment analysis was built in MATLAB that 
takes the integration output files as inputs (Figure 2.4). The tool averages technical 
replicates, calculates fragment error, and performs a weighted or unweighted LSQ 
regression. The hydrogen isotopomers active in the model are adjustable by the user. The 
tool outputs the relative abundance of each hydrogen isotopomer as well as the calculated 
total enrichment at each carbon position of glucose. To evaluate the confidence of the 
estimations, the comparison between MIDM and MIDC are presented to the user in a visual 
way. The complete user manual for this tool can be found in APPENDIX B.  
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Figure 2.4 
The gpa GUI automates positional analysis of glucose. 
 
 
Conclusions and future directions 
 The six glucose derivative fragments necessary for positional enrichment analysis 
can be measured accurately from biological samples, with RMSEs less than 1%. While the 
measurement errors are low, they significantly impact positional enrichment estimates. 
Adapting the algorithm to weight fragments based on inverse RMSE and simplifying the 
number of isotopomers in the model improves estimates. Other computational approaches 
may also improve the robustness of the methodology. Experimental approaches, such as 
adding a solid-phase extraction (80), could be employed to partially purify glucose 
derivatives, remove contaminants, and improve RMSE.  
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Future studies should directly compare the refined GC-MS-based positional 
enrichment methodology with the gold standard method, NMR. The results of this 
comparison would reinforce the utility of the GC-MS-based method. For these studies, 
isotopic tracers (e.g. the tracer set described in CHAPTER IV) could be added to the media 
of isolated rat hepatocytes under gluconeogenic conditions. After a minimum of 8 hours, 
the labeled medium glucose could be analyzed by both GC-MS and NMR. This 
experimental design is advantageous because of the abundance of hepatocytes per isolation 
and the large volume of media per culture dish (~10 mL).  
The induction of glucose production in isolated hepatocytes was successful in a 
pilot experiment without tracers (Figure 2.5). In this experiment, primary hepatocytes were 
isolated from rats. The cell count was quantified microscopically using a hemocytometer. 
The hepatocytes were purified and suspended in attachment media (DMEM) with 20 mM 
of glucose. Approximately five million cells were added to each 10 cm collagen-coated 
dish. After four hours, the attachment media was removed and replaced with a maintenance 
media containing 20 mM glucose. The cells were allowed to recover overnight. Then, the 
maintenance media was removed, and the attached hepatocytes were carefully washed and 
cultured in 10 mL of a 0 mM glucose gluconeogenic media with or without 10 nM of 
glucagon. After one hour, some dishes received the gluconeogenic precursors pyruvate (1 
mM) and lactate (10 mM). 150 µL media samples were obtained every two hours over 24 
hours. The glucose concentration was assessed in duplicate using a YSI 2300 STAT PLUS 
analyzer. 
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Figure 2.5 
Glucose production in cultured hepatocytes under gluconeogenic conditions. Average glucose 
production (nmol/106 cells/hr) ± SEM (n=3) in primary hepatocytes incubated in glucose-free 
media for 8 hours with or without glucogenic precursors and glucagon. The glucose concentration 
was measured in duplicate using a YSI 2300 STAT PLUS analyzer. Letters indicate statistically 
separated groups, as determined by ANOVA and Tukey-Kramer. 
 
 The GC-MS-based methodology is much less time-intensive than the traditional 
NMR-based methodologies. User interface tools built for this project reduce analysis time 
and improve the accessibility of the computational-intensive method. However, method 
time can be reduced further. In all studies reported in this thesis, glucose derivatives were 
analyzed separately by GC-MS. In a pilot study, the derivatives were mixed 1:1:1 in a glass 
GC-MS vial. Clear derivative peaks were identified in the combination run (Figure 2.6), 
and accurate MIDs were obtained. An expanded study would confirm that accurate 
measurements can be obtained from derivative mixtures. Combining derivatives would 
reduce GC-MS run time by more than two-thirds.  
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Figure 2.6  
Chromatogram from a 1:1:1 mixture of glucose derivatives. (A) The total ion chromatogram 
for the analysis run shows many peaks in the expected time window. (B) The SICs from the main 
ion in each derivative reveals three clear peaks. m/z 145 was the main ion for the methyloxime 
pentapropionate (Mox) derivative of glucose (gray), m/z 173 for the aldonitrile pentapropionate 
(Aldo) derivative (red), and m/z 301 for the di-O-isopropylidene propionate (DiO) derivative 
(blue).  
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CHAPTER III 
APPLICATION TO GLUCOSE CYCLING 
 
 The isolated mouse islet studies described in this chapter were published in 
Diabetes in 2015 (71). 
Introduction 
 Glucose-6-phosphatase catalyzes the hydrolysis of glucose-6-phosphate (G6P) to 
glucose and inorganic phosphate (24, 29, 51, 69, 70). It exists as a multi-component system 
located in the endoplasmic reticulum (ER) and is comprised of several integral membrane 
proteins, namely a catalytic subunit (G6PC), a glucose transporter and a G6P/inorganic 
phosphate antiporter (24, 29, 51, 69, 70). Three G6PC isoforms have been identified, 
designated G6PC, G6PC2 and G6PC3 (29).  Each isoform is encoded by a separate gene 
with a distinct pattern of tissue-specific expression (29). G6PC is predominantly expressed 
in liver where it catalyzes the final step in gluconeogenesis and glycogenolysis (24, 29, 51, 
69, 70). G6PC3, also known as UGRP and G6Pase-beta, is ubiquitously expressed (11, 
49). Mutations that reduce G6PC3 activity result in neutropenia, however, the 
physiological function of G6PC3 is unclear (12, 18). G6PC2, also known as IGRP (5, 48), 
is selectively expressed in pancreatic islet beta cells (54). G6PC2 is a major autoantigen in 
both mouse (26, 46, 52) and human (31, 75) type 1 diabetes. 
 Historically the question as to whether glucose-6-phosphatase activity is present in 
islets has been controversial, though it is now generally agreed that activity is detectable, 
but at a lower level than that found in liver (5, 24, 54, 55, 66). While a majority of studies 
agree that glucose-6-phosphatase activity exists in pancreatic islets, the issue as to whether 
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the level of activity is enough to affect glucose-stimulated insulin secretion (GSIS), and 
therefore be of biological significance, is currently unresolved. Matschinsky and 
colleagues (66) concluded that, while glucose-6-phosphatase activity is present in rat islets, 
the level of activity is not enough to result in sufficient G6P hydrolysis so as to affect GSIS. 
However, two caveats have subsequently arisen with respect to this conclusion. First, in 
contrast to all other vertebrate species examined (see http://genome.ucsc.edu/), G6PC2 is 
a pseudogene in rats (48). Second, in various rat models associated with impaired glucose 
tolerance, G6PC expression is induced such that G6P hydrolysis would be elevated (38, 
44, 68).  
 Several papers have also addressed the issue of G6P hydrolysis in mouse islets. 
Early studies suggested that, even though glucose-6-phosphatase activity is present in 
mouse islets, G6P hydrolysis does not occur (6). While seemingly counterintuitive, such a 
scenario would be possible if G6P entry into the ER lumen was blocked. However, later 
studies challenged this conclusion and showed that the measurement of G6P hydrolysis 
within islets is critically dependent on assay conditions (15, 36). More recently the O’Brien 
lab has shown that G6pc2 accounts for the low glucose-6-phosphatase enzyme activity 
detected in mouse islets (57) and that a global knockout of G6pc2 in mice on both a mixed 
(72) and pure C57BL/6J genetic background (57) results in a mild metabolic phenotype 
characterized by a ~15% decrease in FBG. These knockout mouse data are consistent with 
recent genome wide association studies (GWAS) showing that single nucleotide 
polymorphisms (SNPs) within the human G6PC2 gene are associated with variations in 
FBG (10). Based on these observations, we hypothesize that G6PC2 forms a futile substrate 
cycle with the beta cell glucose sensor, glucokinase (30, 50), and acts as a negative 
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regulator of basal GSIS by hydrolyzing G6P, thereby modulating beta cell glycolytic flux 
(57). Consistent with this model, a reduction in G6pc2 expression results in a leftward shift 
in the dose response curve for GSIS, such that under fasting conditions blood glucose levels 
are reduced (57).    
 A major caveat with this model for the function of G6PC2 is the fact that estimates 
of glucose cycling obtained by radiotracer studies of pancreatic islets are very low (15, 36). 
Because the glucose-6-phosphatase activity of G6PC2 is ~40 fold lower than that of G6PC 
(57) and because G6PC2 also possesses a phosphatidic acid phosphatase domain (49), the 
possibility exists that G6PC2 influences GSIS through a mechanism independent of its 
ability to hydrolyze G6P. We have revisited this issue using an alternate, novel stable 
isotope methodology. With this approach, we can demonstrate much higher levels of 
glucose cycling in islets than previously reported. Importantly, glucose cycling is abolished 
in G6pc2 KO mouse islets, suggesting that G6pc2 modulates GSIS, at least in part, through 
its ability to hydrolyze G6P and thereby oppose the action of the beta cell glucose sensor, 
glucokinase (Figure 3.1).  
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Figure 3.1 
Glucose cycling is controlled by the action of glucokinase and G6PC2. Tracer glucose (D7-
glucose) is converted to glucose-6-phosphate (D7-G6P) through the action of the enzyme 
glucokinase (GK) at rate v1. G6P is assumed to fully equilibrate with fructose-6-phosphate (F6P). 
The phosphoglucoisomerase (PGI)-catalyzed isomerization of G6P to F6P results in exchange of 
hydrogen at the second carbon (C2) of G6P. Any deuterium at C2 derived from the D7-glucose 
tracer is replaced by an unlabeled hydrogen derived from water during the reverse isomerization 
reaction. The action of G6PC2 counteracts the activity of GK, converting G6P to glucose at rate v2. 
The rate of net uptake of glucose is denoted vnet, which is equal to v1 minus v2. Black circles 
represent a carbon bound to deuterium, and white circles represent a carbon with hydrogen bound. 
 
 
Experimental design 
Animal care 
 The animal housing and surgical facilities used for this study meet the standards set 
by the American Association for the Accreditation of Laboratory Animal Care standards. 
The Vanderbilt University Medical Center Animal Care and Use Committee approved all 
protocols used. Prior to islet isolation, mice were maintained either continuously on a 
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standard rodent chow diet (calorie contributions: 28% protein, 12% fat, 60% carbohydrate 
(14% disaccharides); LabDiet 5001; PMI Nutrition International) or on a high-fat diet 
(calorie contributions: 15% protein, 59% fat, 26% carbohydrate (42% disaccharides); 
Mouse Diet F3282; BioServ) for 5-8 months. Food and water were provided ad libitum. 
 
Generation of G6pc2 knockout (KO) mice 
 The generation of G6pc2 KO mice on a pure C57BL/6J genetic background has 
been previously described (57, 72). 
 
Islet isolations 
 Islets were isolated from adult (8-12 months) male wild type and G6pc2 KO mice 
as previously described (57). Isolated islets were incubated overnight in petri dishes in 
RPMI-1640 medium containing 11 mM glucose. Aliquots of ~100 islets were then 
transferred to 96 well plates and incubated for 24 or 72 hr in RPMI-1640 medium 
containing 5 mM or 11 mM glucose in a volume of 175 µl. Islets were incubated in either 
naturally labeled glucose or [1,2,3,4,5,6,6-2H7]glucose (D7-glucose) (98% isotopic purity 
per site; Cambridge Isotope Laboratories, Inc., Andover, MA, USA). Following the 24 or 
72 hr incubation, islets were resuspended by pipetting and pelleted by centrifugation. The 
supernatant was retained for analysis of insulin content and glucose isotopomers, whereas 
the cell pellet was washed in PBS and then solubilized in passive lysis buffer (Promega) 
before quantitation of protein content using the Bio-Rad colorimetric protein assay. 
 
 
 26 
 
Preparation of glucose derivatives 
 Derivatization was performed as described in CHAPTER II with one addition to 
the Di-O-isopropylidene propionate protocol. For this derivatization, 20 µl of supernatant 
was mixed with 20 µl of 5 mM [U-13C6; 1,2,3,4,5,6,6-
2H7]glucose (Cambridge Isotope 
Laboratories, Inc., Andover, MA, USA), which served as an internal standard. The 
derivatization then proceeded as described previously to produce glucose 1,2,5,6-di-
isopropylidene propionate.  
 
GC-MS analysis 
 GC-MS analysis of the glucose derivatives was performed as described in 
CHAPTER II. 
 
Estimation of total glucose concentration in the presence of deuterated glucose 
 Because enzymatic methods for glucose quantification are sensitive to kinetic 
isotope effects, we used a GC-MS-based method for quantification. The di-O-
isopropylidene glucose peak was integrated over a mass range from m/z 301 (M+0) to 321 
(M+20), and the ratio of the integrated ion counts of the glucose in the medium supernatant 
(M+0 to M+10) to the fully labeled [U-13C6; 1,2,3,4,5,6,6-
2H7]glucose internal standard 
(M+11 to M+20) was determined. We used known glucose standards that were derivatized 
and analyzed alongside the experimental samples in each run to build a standard curve as 
shown in Equation 3.1, 
[Sample]
[INSTD]
= 𝑘
∑ (𝑀 + 𝑖)10i=0
∑ (𝑀 + 𝑖)20i=11
+ 𝑏 (3.1) 
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where [Sample] is the concentration of glucose in the supernatant sample, [INSTD] is the 
known concentration of the internal standard, (M + i) is the relative abundance of the ith 
mass isotopomer, k is the slope of the calibration curve, and b is its y-intercept. Cell-free 
evaporation controls were collected at 24 and 72 hours from replicate wells. The glucose 
concentration of these unlabeled samples was measured with a YSI 2300 STAT Plus 
Glucose & Lactate Analyzer. An evaporation correction factor was calculated by dividing 
the average concentration of the 72-hour cell-free controls by the average concentration of 
the 24-hour cell-free controls, and all 72-hour sample concentrations were divided by the 
correction factor. 
 
Calculation of glucose uptake and cycling 
 Net glucose uptake (vnet) was calculated from the change in medium glucose 
concentration from 24 hours to 72 hours and expressed in picomoles/islet/hour using 
Equation 3.2,  
𝑣𝑛𝑒𝑡 =
𝐶72 − 𝐶24
48 ℎ𝑟𝑠
×
𝑉
𝑁
 (3.2) 
 
where C72 is the extracellular glucose concentration at 72 hrs, C24 is the glucose 
concentration at 24 hrs, V is the liquid volume in each well (=175 μL), and N is the number 
of islets in each well. The rate of glucose cycling (GC) was expressed as a percentage of 
glucose uptake v2/vnet using an equation derived from the model illustrated in Figure 3.1.  
Using the glucose concentration and relative isotopomer abundance measurements, 
GC was calculated according to Equation 3.3: 
𝐺𝐶 =  
𝑣2
𝑣𝑛𝑒𝑡
=
𝑦72 − 𝑦24
𝑥72 − 𝑥24
 (3.3) 
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where 
𝑦 = ln (
𝐴
𝐴 + 𝐵
) (3.4) 
 
and 
𝑥 = ln (𝐶) (3.5) 
 
In Equation 3.3, y represents the natural logarithm of the ratio of M+7 glucose abundance 
(A) to total M+1 through M+7 abundance (A+B) (Equation 3.4), and x is the natural 
logarithm of the glucose concentration C (Equation 3.5). The subscripts on x and y 
represent the time at which each measurement was taken. Equation  3.3 was applied to 
estimate GC by using the measured di-O-isopropylidene glucose MIDs, corrected for 
natural isotope abundance (23), to calculate the relative abundances B (m/z 302 to 307) and 
A (m/z 308). The derivation of Equation 3.3 is shown in APPENDIX C. 
 
Calculation of positional enrichment 
 The MIDs of six ion fragments, m/z 145, 173, 259, 284, 301, and 370, derived from 
all three glucose derivatives were compiled into a matrix and compared to theoretical 
distributions using a custom least-squares regression program described in CHAPTER II 
(Figure 1.2). The program was used to estimate the relative abundance of each of the 128 
possible hydrogen isotopomers of glucose.  
 
Statistical analyses 
 Data were analyzed using a two-tailed Student's t-test: two sample assuming equal 
variance. The level of significance is indicated in the figure legends.   
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Quantification of glucose cycling in WT and G6pc2 KO islets isolated from CF mice 
 During incubations with isolated islets, lower mass isotopomers of glucose would 
be expected to accumulate in the culture medium if a D7-glucose tracer is converted to D7-
G6P through the action of glucokinase but is then converted back to D6-glucose through 
the action of G6pc2 (Figure 3.1). To address this hypothesis, we incubated wild type (WT) 
and G6pc2 knockout (KO) islets, isolated from CF mice, in the presence of 5 mM D7-
glucose and measured the MIDs of medium glucose samples collected at 24 and 72 hours. 
We first examined the MIDs obtained from integrating the glucose 1,2,5,6-di-
isopropylidene propionate derivative peak, which preserves all 7 carbon-bound hydrogen 
atoms from the parent glucose molecule. After correcting for natural isotope abundance, 
we summed the relative abundances of the lower mass isotopomers from m/z 302 (M+1) 
to m/z 307 (M+6) and normalized them to the total labeled glucose signal from M+1 to 
M+7. The results show a significant accumulation of total M+1 to M+6 isotopomers in the 
incubation media from WT islets but no increase in the media from KO islets (Figure 3.2A).  
 Next, we examined the positional 2H enrichment. Our model suggests that cycling 
of D7-glucose should result in accumulation of a specific M+6 mass isotopomer of glucose 
with deuterium replaced by hydrogen at the C2 position (i.e., [1,3,4,5,6,6-2H6]glucose). 
Least-squares regression analysis using mass isotopomer data obtained from three glucose 
derivatives (Figure 1.2) enabled us to calculate the 2H enrichment at each carbon position 
of glucose in the culture media. This calculation confirmed that loss of deuterium at the C2 
position of glucose from the fully labeled D7-glucose tracer accounted for the majority of 
the lower mass isotopomers that were formed in the media from WT islet incubations 
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(Figure 3.2B). Accumulation of the [1,3,4,5,6,6-2H6]glucose mass isotopomer was not 
observed in the media from KO islet incubations (Figure 3.2B). 
 
Figure 3.2 
Glucose cycling in WT or G6pc2 KO islets isolated from chow fed mice and incubated in 5 
mM D7-glucose. A: The average relative abundance of lower mass isotopomers (M+1 to M+6) of 
the 1,2,5,6-di-isopropylidene propionate derivative fragment in the media from WT (black squares) 
or KO (white circles) islet incubations at 24 and 72 hours. The relative abundances are corrected 
for natural stable isotope labeling (23) and normalized to the total labeled glucose signal from M+1 
to M+7. The average relative abundance of the 24-hour KO samples was baseline subtracted to 
correct for the isotopic purity of the D7-glucose tracer. In all experiments where tracer control 
samples were analyzed, the mass isotopomer distribution (MID) of the 24-hour KO samples was 
nearly identical to the MID of the pure D7-glucose tracer. B: The average estimated abundance ± 
SEM of the [1,3,4,5,6,6-2H6] glucose isotopomer with deuterium loss at C2 in the media from WT 
(black bar) or KO (white bar; all experiments reported zero abundance) islet incubations at 72 
hours. C: Average glucose cycling ± SEM, reported as a percentage of net glucose uptake. WT, 24 
hours n=4; WT, 72 hours n=4; KO, 24 hours n=4; KO, 72 hours n=4 incubations of 100 islets. *P 
< 0.05 vs. WT. 
 
 Finally, using Equations 3.3-3.5, we calculated the rate of glucose cycling relative 
to net glucose uptake (Table 3.1) and found that WT islets exhibited cycling rates that were 
~16% of the net uptake (Figure 3.2C). This is much higher than the 3% rate of glucose 
cycling previously reported by Khan et al. (37), who used a radiotracer method to quantify 
glucose cycling in islets isolated from CF mice and incubated in 5.5 mM glucose. In 
contrast, glucose cycling in KO islets was negligible (Figure 3.2C). Taken together, these 
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findings are consistent with our hypothesis that G6PC2 acts by hydrolyzing G6P, thereby 
opposing the action of glucokinase.  
 
Quantification of glucose cycling in WT and G6pc2 KO 
islets isolated from HFF mice 
 
Both WT and G6pc2 KO mice fed a high fat diet have a ~100 mg/dl elevation in 
FBG, though, as in CF mice, FBG remains ~20 mg/dl lower in G6pc2 KO mice compared 
to WT mice (26). Based on this observation, we hypothesized that the rate of G6P 
hydrolysis (v2) would be similar in CF and HFF mouse islets. To address this hypothesis, 
we applied our stable isotope method to islets isolated from HFF mice.  
Consistent with our model for the action of G6PC2 on glucose cycling, M+1 to 
M+6 glucose isotopomers accumulated in the media between 24 and 72 hours in WT islet 
incubations only (Figure 3.3A). Further validation of the cycling model was provided by 
the positional 2H enrichment results, which showed that the relative abundance of the 
[1,3,4,5,6,6-2H6] glucose isotopomer with deuterium loss at the second carbon was greater 
in the WT islet incubations compared to the KO islet incubations (Figure 3.3B). We again 
calculated the rate of glucose cycling relative to net glucose uptake. As expected, and 
consistent with the similar accumulation of M+1 to M+6 isotopomers observed in the HFF 
incubations (Figure 3.3A), the rate of G6P hydrolysis (v2) was nearly identical between CF 
and HFF islets in 5 mM glucose (Table 3.1). Net glucose uptake (Table 3.1) and glucose 
cycling (Table 3.1) were not statistically different between CF and HFF islets. As in CF 
islets, glucose cycling was completely abolished in KO islets from HFF mice (Figure 
3.3C). 
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Figure 3.3 
Glucose cycling in WT or G6pc2 KO islets isolated from high fat fed mice and incubated in 5 
mM D7-glucose. Panels A, B, and C show the same data as described in Error! Reference source 
ot found., but using islets obtained from high fat fed mice. WT, 24 hours n=5; WT, 72 hours n=5; 
KO, 24 hours n=5; KO, 72 hours n=5 incubations of 100 islets. *P < 0.05 vs. WT. 
 
Quantification of the influence of extracellular glucose 
concentration on glucose cycling 
 An analysis of insulin secretion from perfused WT and G6pc2 KO mouse pancreata 
suggests a parallel shift in the dose response curve for GSIS to the left in the KO pancreata 
when glucose increased from 5 to 11 mM (57). This parallel shift is indicative of a fixed 
rate of G6P hydrolysis (v2), since v1 should be the same in both WT and KO pancreata at 
the same glucose concentration with the difference in GSIS between the two curves being 
solely attributable to v2 (Figure 3.4). This situation could arise if either transport of G6P 
into the ER lumen or hydrolysis of G6P to glucose by G6pc2 was operating at Vmax, the 
latter being supported by enzymatic studies (56). Based on this observation, we 
hypothesized that the rate of G6P hydrolysis (v2) would be similar at 5 and 11 mM and that 
the glucose cycling rate (v2/vnet) would be reduced in response to the expected increase in 
glucose uptake (vnet) at elevated glucose concentration. To address this hypothesis, glucose 
cycling was assessed at 11 mM glucose using islets isolated from CF and HFF mice. 
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Figure 3.4 
Simulation of GSIS dose-response curve shifting in the linear range. Total glucose uptake (v1) 
is driven by the glucose sensor glucokinase and is assumed to be directly proportional to the glucose 
concentration (x-axis) and independent of genotype. In WT islets, the hydrolysis of G6P by G6pc2 
(v2) opposes v1 and reduces glycolytic flux (vnet), which is equal to v1-v2. In KO islets, v2 is assumed 
to be zero and vnet is therefore equal to v1. vnet is assumed to be directly proportional to insulin 
secretion (y-axis). The simulation is based on the expectation that vnet should be greater in G6pc2 
KO islets at any given glucose concentration in the linear range. The experimental observation that 
vnet is the same for WT and G6pc2 KO islets suggests that islets have adapted to prolonged culture. 
In (A), v2 is fixed at a constant rate in the WT simulation and is set to zero in the KO simulation. 
The KO dose-response curve shifts parallel to the WT curve. Because v1 and therefore vnet increases 
as the glucose concentration increases, the glucose cycling rate (v2/vnet) decreases as glucose 
concentration increases. In (B), glucose cycling (v2/vnet) is fixed at a constant value in the WT 
simulation and set to zero in the KO simulation. The KO dose-response curve shifts from the WT 
curve in a non-parallel manner, as the rate of G6P hydrolysis (v2) increases with net glucose uptake 
(vnet). In (C), glucose cycling increases with glucose concentration, simulated by increasing v2 over 
the glucose concentration range. The WT and KO curves diverge significantly at higher glucose 
concentrations, and the WT dose-response curve loses its linearity.  
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Figure 3.5  
Glucose cycling in WT or G6pc2 KO islets isolated from chow fed mice and incubated in 11 
mM D7-glucose. Panels A, B, and C show the same data as described in Error! Reference source 
ot found., but using islets obtained from high fat fed mice. WT, 24 hours n=5; WT, 72 hours n=5; 
KO, 24 hours n=4; KO, 72 hours n=4 incubations of 100 islets. *P < 0.05 vs. WT. 
 
If the rate of G6P hydrolysis (v2) was similar in the 5 mM and 11 mM incubations, 
as hypothesized, the accumulation of M+1 to M+6 isotopomers of glucose in the medium 
would be similar. However, a significant increase in the accumulation of M+1 to M+6 
isotopomers, consistent with an increase in G6P hydrolysis (v2), was observed in CF 
(Figure 3.5A) and HFF (Figure 3.6A) islets. Even at the early 24 hour time point, the 
accumulation of M+1 to M+6 isotopomers in the media is significant in CF (Figure 3.5A) 
and HFF (Figure 3.6A) WT incubations, while the abundance of M+1 to M+6 isotopomers 
in KO incubations does not change from the baseline observed in the 5 mM glucose 
experiments (Figure 3.5A, Figure 3.6A). The accumulated M+1 to M+6 isotopomers in the 
WT media contain a significant abundance of the model-predicted [1,3,4,5,6,6-2H6] 
glucose isotopomer with deuterium loss at the second carbon position, while this 
isotopomer is not present in the KO incubations (Figure 3.5B and Figure 3.6B). 
Unexpectedly, both CF and HFF WT islets exhibited increased cycling, relative to CF islets 
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in 5 mM glucose, driven by the significant increase in G6P hydrolysis (v2), with rates 
quantified as ~35-40% of net uptake (Figure 3.5C and Figure 3.6C). Once again, the 
cycling in KO islets was negligible (Figure 3.5C and Figure 3.6C).  
 
 
Figure 3.6  
Glucose cycling in WT or G6pc2 KO islets isolated from high fat fed mice and incubated in 
11 mM D7-glucose. Panels A, B, and C show the same data as described in Error! Reference 
ource not found., but using islets obtained from high fat fed mice and incubated at 11 mM glucose.  
WT, 24 hours n=7; WT, 72 hours n=7; KO, 24 hours n=7; KO, 72 hours n=7 incubations of 100 
islets. *P < 0.05 vs. WT.  
 
 
Table 3.1  
Comparison of glucose cycling and uptake among experimental groups 
 
  Rate of G6P Hydrolysis, v2 
(pmol/islet/hr) 
Glucose Uptake, vnet 
(pmol/islet/hr) 
Glucose Cycling (%) v2/vnet 
Diet 
[Glc] 
(mM) 
WT G6pc2 KO WT G6pc2 KO WT G6pc2 KO 
CF 5 2.7 ± 0.4 (4)A 0.1 ± 0.3 (4) 18 ± 1 (4)A 14 ± 3 (4)A 16 ± 4 (4)A    2 ± 2 (4) 
HFF 5 3.1 ± 0.1 (5)A 0.1 ± 0.3 (5)  14 ± 2 (5)A 14 ± 3 (5)A 25 ± 3 (5)A/B 0.5 ± 2 (5) 
CF 11     11 ± 1 (5)B 0.9 ± 0.3 (4)  28 ± 4 (5)A/B 31 ± 5 (4)A/B 40 ± 6 (5)B    3 ± 1 (4) 
HFF 11     14 ± 1 (7)B 1.2 ± 0.4 (7)  45 ± 8 (7)B 46 ± 9 (7)B 35 ± 5 (7)B    3 ± 1 (7) 
Rate of G6P hydrolysis, glucose uptake and cycling results reported as mean ± SEM with the 
number of incubations indicated in parentheses. In each column, groups were compared by 
ANOVA. If at least one mean was significantly different, pairwise comparisons were performed 
by Tukey-Kramer. Statistically separated groups are indicated by letters. 
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Conclusions of isolated mouse islet experiments 
 This study describes a novel method for quantifying glucose cycling in isolated 
pancreatic islets that is based on the use of a stable D7-glucose tracer and the model 
presented in Figure 3.1. We applied this method to islets isolated from WT and G6pc2 KO 
mice to investigate the role of G6pc2 in glucose cycling. In all WT islet incubations, a 
significant accumulation of M+1 to M+6 glucose isotopomers was observed over 72 hours 
(Figure 3.2A, Figure 3.3A, Figure 3.5A, and Figure 3.6A), and a specific, model-predicted 
D6-glucose isotopomer, [1,3,4,5,6,6-2H6] glucose, accounted for most of the cycled 
glucose (Figure 3.2B, Figure 3.3B, Figure 3.5B, and Figure 3.6B), as determined by a 
custom least squares regression algorithm (Figure 1.2). Glucose cycling in WT islets varied 
with the assay conditions and was estimated to be 16 to 40% of net glucose uptake (Table 
3.1). G6pc2 KO islets took up glucose from the media at rates similar to WT islets (Table 
3.1), but no accumulation of M+1 to M+6 glucose isotopomers was observed (Figure 3.2A, 
Figure 3.3A, Figure 3.5A, and Figure 3.6A), and glucose cycling was negligible (Table 
3.1). These observations are consistent with our hypothesis that G6PC2 controls glucose 
cycling by opposing the action of glucokinase, thereby regulating glycolytic flux and 
ultimately GSIS. In this manner, G6PC2 may play an important role in the regulation of 
FBG, a hypothesis supported by GWAS data linking G6CP2 to FBG in humans (9, 10).     
WT islets isolated from CF mice and incubated in 5 mM glucose cycled ~16% of 
the net glucose uptake (Figure 3.2). Previous studies using tritiated water quantified 
glucose cycling in isolated islets by measuring 3H incorporation at carbon 2 of derivatized 
glucose (37, 38). This method was not sensitive enough to quantify cycling in 3 hour, 5.5 
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mM glucose incubations using islets isolated from lean, WT mice, but based on 
extrapolation of data derived from ob/ob mouse islets, was used to estimate WT cycling 
rates at 3-4% of total uptake (37). While our novel method for measuring glucose cycling 
using stable isotopes requires longer incubation times, the simplicity and sensitivity are 
distinct advantages. Both the tritiated water method (37) and our method for measuring 
glucose cycling rely on the assumption that G6P and fructose-6-phosphate are in a rapid 
and complete equilibrium. However, hydrogen isotopes alter the kinetics of the PGI 
reaction such that equilibrium may not be complete. Nevertheless, previous work suggests 
the kinetic isotope effect of tritium reduces the Vmax of the PGI reaction more than 
deuterium (47), which potentially makes our stable isotope method more accurate in 
applying this assumption. We expect that the rates of other reactions in our model, 
including the reactions catalyzed by glucokinase (v1) and G6pc2 (v2), would be minimally 
affected by the presence of either 2H or 3H tracers because they do not involve hydrogen 
transfer. Both methods only account for G6P molecules that are completely cycled out of 
the cell and subsequently accumulate in the culture medium. Therefore, the calculated rates 
of glucose cycling will underestimate the true cycling rate catalyzed by G6pc2 if some of 
the resulting glucose molecules are redirected toward an alternative intracellular fate and 
do not reappear in the extracellular medium. 
To investigate the effect of diet on glucose cycling, islets were isolated from HFF 
mice. Similar increased rates of G6P hydrolysis were observed in CF and HFF islets when 
glucose was increased from 5 mM to 11 mM glucose (Table 3.1), consistent with our 
previous observation that the difference in FBG between WT and G6pc2 KO mice is 
similar on both diets despite elevated FBG in the HFF groups (37). Interestingly, previous 
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studies reported a significant increase in glucose cycling in islets isolated from obese ob/ob 
mice relative to WT (15, 36, 37, 39, 40). Kahn et al. (39) showed that this increase was not 
due to hyperglycemia, which is characteristic of ob/ob mice. However, whether 
hyperlipidemia or the absence of leptin signaling influence glucose cycling in ob/ob mice 
is unclear. Furthermore, the magnitude of this previously reported enhancement of glucose 
cycling in ob/ob mouse islets could, in part, be due to the underestimation of cycling in 
lean, WT mice. 
Our method requires 72 hr islet incubations in order to enrich the medium in lower 
mass isotopomers of glucose for quantification. Over this time period in non-physiological 
conditions, the data suggest that the islets are losing some of their in vivo characteristics. 
G6pc2 KO mice have a significantly lower FBG than their WT littermates (57), and 
consistent with this finding, isolated KO islets exhibited increased glycolytic flux (data not 
shown) and insulin secretion (57) in acute assays. However, after 72 hr in culture, insulin 
secretion between the WT and KO islets normalizes such that the concentration of insulin 
in the medium is not significantly different between WT and KO islets. In addition, the 
estimated net uptake rate of glucose between 24 and 72 hours in WT and G6pc2 KO islets 
is equivalent (Table 3.1). While these glucose uptake data are consistent with the insulin 
secretion data (data not shown), the acute insulin secretion assays predict increased glucose 
uptake in G6pc2 KO relative to WT islets. Similarly, a surprising elevation in the rate of 
G6P hydrolysis was observed in CF and HFF islets incubated in 11 mM glucose (Figure 
3.5A and Figure 3.6A, Table 3.1). This observation is at odds with perfused pancreas data 
showing a parallel, leftward shift in the dose response curve for GSIS in CF G6pc2 KO 
mice (26). In combination, these observations suggest that the islets are undergoing 
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adaptation during the long assay incubation. We hypothesize that the KO islets adapt to the 
absence of G6pc2 by reducing glucose uptake, which would make biological sense in that 
elevated glucose metabolism has been shown to be toxic to beta cells (19). We also 
hypothesize that the ability of glucose to stimulate G6pc2 expression (56) may explain the 
increase in v2. This induction would not have been a factor in acute insulin secretion 
experiments, given their short time course. Addressing these hypotheses and the molecular 
mechanisms behind islet adaptation to prolonged culture are clearly of interest and will be 
the subject of future experiments. Given these apparent effects of the long incubation time 
and any limitation in gas exchange in the 96 well plates used for the assay, future work will 
focus on using microfluidic devices specifically designed for islet culture (20, 59) allowing 
the media volume, and thus the time in culture, to be reduced. Such experiments would 
also reveal whether the significant increase in glucose uptake at 11 mM in HFF islets but 
not CF islets (Table 3.1) is also an artifact of the long incubation times. 
In conclusion, the data presented in this study suggest that glucose cycling in WT 
islets is greater than previously reported and that G6pc2 is responsible for this cycling. 
These findings are consistent with the GWAS studies linking G6PC2 to regulation of FBG 
(9, 10, 16). 
Future directions 
Revise experimental design to remove m/z 145 fragment contamination 
We chose D7-glucose as the tracer in the glucose cycling experiments so that all 
major cycling products could be identified in an unbiased manner. Our studies support the 
hypothesized model (Figure 3.1). The only significant cycling product that accumulated in 
the media was [1,3,4,5,6,6-2H6]glucose. The positional analysis methodology successfully 
 40 
 
measured the abundance of this specific cycling product. However, the error associated 
with these measurements was significant. Further analysis revealed that the m/z 145 
fragment from the glucose methyloxime pentapropionate derivative was contaminated by 
a lower mass fragment that shifts into the analytical range.  
In unlabeled glucose, the major ion in the methyloxime derivative is m/z 145 
(Figure 3.7A). Lower mass ions m/z 141 and m/z 142 are present but do not significantly 
interfere with the MID of m/z 145. The methyloxime fragment from D7-glucose shifted 
from m/z 145 to m/z 147 as this fragment contained two 2H (Figure 3.7B). m/z 146 is 
present at significant abundance due to the inherent impurity of the tracer. The m/z 141 
and 142 ions present in the unlabeled spectra were not present in the spectra from D7-
glucose. We hypothesized that m/z 141 shifted to m/z 143 and that m/z 142 shifted to m/z 
145. The relative abundance of m/z 145 is far more significant than expected. 
Computational fragment analysis (73) predicted that the m/z 142 ion contains carbons 3, 
4, and 5. While not conclusive, analysis of the methyloxime derivative from [1,2-
13C2]glucose showed the mass shift to m/z 147 expected from the main ion with no change 
in the relative abundances of m/z 141 and m/z 142 (Figure 3.7C). Future studies could use 
a customized, lower enrichment tracer to eliminate the interference from m/z 142 at the 
risk of losing the ability to identify all potential cycling products. Computational correction 
methods could also be pursued, or a different derivatization method could be sought to 
identify a different fragment consisting of the same two carbons.   
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Figure 3.7  
Glucose methyloxime pentapropionate mass spectra from unlabeled and tracer glucose.  
  
Determine the effect of glucocorticoid treatment on glucose cycling 
Multiple glucocorticoid response elements (GREs) are present in the promotor 
region of G6PC2 (42). Previous work showed insulin secretion was significantly reduced 
and G6pc2 activity was significantly elevated in isolated islets from glucocorticoid-treated 
ob/ob mice compared to untreated ob/ob mice (32). Similar results were reported for 
transgenic mice overexpressing the glucocorticoid receptor, increasing the glucocorticoid 
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sensitivity of isolated islets (39). We hypothesize that glucose cycling will increase in 
response to glucocorticoid treatment and that our sensitive methodology will be able to 
quantify this increase in islets isolated from CF WT mice. We further hypothesize that no 
increase in glucose cycling will be observed in islets isolated from treated G6pc2 KO mice. 
 
Investigate glucose cycling in isolated human islets 
The isolated islet studies described above provide strong evidence that G6pc2 can 
modulate GSIS by cycling glucose in mice. We hypothesize that human G6PC2 has a 
similar functional role. GWAS studies support this hypothesis (9, 10, 16). To test this 
hypothesis, isolated islet incubations will be performed, as described above, in 
collaboration with the laboratory of Dr. Alvin Powers, the Integrated Islet Distribution 
Program, and the Human Islet Research Network. Human islets will be tested from a 
variety of donors. A normal range of glucose cycling from healthy, adult donors will be 
determined. Then, it will be determined if glucose cycling is aberrant in islets from donors 
who had type 2 diabetes. Glucose cycling rates will be correlated with GSIS (7, 35) and 
with G6PC2 activity (42). 
In a pilot study, human islets isolated from non-diabetic donors were incubated in 
D7-glucose. Initially, samples were obtained at 24 and 48 hours, as in the isolated mouse 
islet studies. However, over this time period, glucose was almost completely depleted from 
the media, suggesting that the human islets are more metabolically active than the mouse 
islets. The protocol was revised to sample at 6 and 12 hours. Cycling and uptake were 
calculated as described above.  
 43 
 
The accumulation of lower mass isotopomers of glucose was obvious over time in 
the human islet samples, strongly supporting our hypothesis that G6PC2 is cycling glucose 
in human islets. Positional analysis supported the model of cycling, although more work is 
needed for confirmation. Significant variability was observed among the islets (Table 3.2). 
The effect of glucose concentration was not clear from the limited number of samples. 
Genetic differences may account for the variability. We also believe that cycling and 
uptake may trend with the islet profiles identified by Powers and colleagues (35); the 
secretory profile number was included in the preliminary data shown in Table 3.2. 
Additional experiments are necessary to understand the variability.  
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Measure 2H labeling in intracellular metabolites to validate model  
The model of glucose cycling detailed in Figure 3.1 may be too simple to capture 
the dynamics of glucose flux and cycling. Because we only measure the accumulation of 
extracellular glucose cycling products, the measurements may underestimate the true 
cycling rate. Alternatively, intracellular metabolite extraction and the measurement of 2H 
labeling (21, 22, 53, 67) may be required to understand how D7-glucose is utilized and to 
quantify the flux through G6PC2.  
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CHAPTER IV 
APPLICATION TO METABOLIC FLUX ANALYSIS 
 
 Portions of the work described in this chapter were published in The American 
Journal of Physiology – Endocrinology and Metabolism in 2015 (27). 
 
Introduction 
Several NMR-based methods for phenotyping hepatic glucose production in vivo 
utilize three stable isotope tracers: 2H or 13C-labeled glucose, 2H2O, and [U-
13C3]propionate 
(34). Each tracer serves a distinct purpose. [U-13C3]propionate labels CAC metabolites and 
2H2O labels intermediates of GNG. The glucose produced by the liver therefore has a 
distinct labeling pattern that is carbon-source and pathway dependent. The 2H or 13C-
labeled glucose is infused at a constant rate and acts as an internal standard, allowing for 
the calculation of absolute flux rates. This three tracer methodology has been used to 
quantify CAC and GNG fluxes in fasted rats (32, 33), humans (65), and, to a limited extent, 
mice (61). However, the sensitivity limitations of NMR prevent the widespread application 
of this technique to the mouse. The large plasma blood volumes required for NMR analysis 
inflicts stress that disrupts metabolism and obviates replicate sampling. We hypothesized 
that the six glucose derivative fragments (Figure 1.1) would provide sufficient information 
for flux analysis. The lower volume requirements make the GC-MS-based method easily 
applicable to the mouse. The tool significantly enhances the ability to assess in vivo hepatic 
metabolism in wild-type and transgenic mice as well as in mouse models of human disease.  
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Modeling hepatic glucose production in INCA 
A model of hepatic glucose production (Figure 4.1) was constructed using the 
INCA software package (33) (accessible at http://mfa.vueinnovations.com/mfa). The 
hydrogen and carbon transitions were defined for each reaction (Table 4.1). The model is 
based on the reaction network of Jones et al. (34) and assumes: (A) full equilibration of 
four-carbon intermediates in the CAC; (B) complete equilibration between glucose-6-
phosphate (G6P) and fructose-6-phosphate (F6P) by phosphoglucoisomerase (PGI); (C) 
complete equilibration between glyceraldehyde-3-phosphate (GA3P) and 
dihydroxyacetone phosphate (DHAP) by triose phosphate isomerase (TPI); (D) no entry of 
labeled carbon from acetyl-CoA; (E) no re-entry of CO2 formed in the reaction network. 
The model consisted of 19 biochemical reactions (Table 4.1), 22 metabolite nodes, and 424 
mass isotopomer balance equations. Metabolites with equivalent atoms were defined 
(Table 4.2). A description of the mathematical modeling approach applied to these studies 
is provided in APPENDIX E. The MIDs obtained from integration of GC-MS ion traces 
were imported into INCA. The flux through each reaction was estimated (Figure 4.2), 
relative to VCS, by minimizing the sum-of-squared residuals (SSR) between simulated and 
experimental data. Flux estimates were repeated 25 times from random initial values. 
Goodness-of-fit was assessed by a chi-square test with 22 degrees of freedom (i.e. the 
regressions were overdetermined by 22 measurements). 95% confidence intervals were 
computed by evaluating the sensitivity of the SSR to variations in the flux values. The 
relative fluxes were converted to absolute fluxes in µmol/kg/min using the known [6,6-
2H2]-glucose infusion rate (VINF, Figure 4.1), and the mouse weights were used to convert 
fluxes to µmol/min.  
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Figure 4.1  
Model of hepatic glucose production during fasting. 13C from [U-13C3]-propionate enters the 
citric acid cycle as succinyl-CoA (SucCoA) at rate VPCC. Lactate, amino acids, fatty acids, glycerol, 
and glycogen are also modeled as carbon sources for glucose production. 2H incorporation from 
2H2O occurs during gluconeogenesis. The rate of glucose production is estimated as VEndoRa. [6,6-
2H2]-glucose (Glc.inf) is infused at rate VINF.   
 
Key: Endogenous glucose production (VEndoRA), infusion of [6,6-2H2]-glucose (VINF), flux from 
glycogen to glucose-6-phosphate (G6P) (VPYGL), glycerol to dihydroxyacetone phosphate (DHAP) 
(VGK), phosphoenolpyruvate (PEP) to glyceraldehyde-3-phosphate (GA3P) (VENOL), oxaloacetate 
(Oac) to PEP (VPCK), pyruvate (Pyr) to Oac (VPC), Oac and acetyl-coA (AcCoA) to citrate (Cit) 
(VCS), propionyl-CoA (PropCoA) to succinyl-CoA (SucCoA) (VPCC), SucCoA to Oac (VSDH), the 
joint contribution of pyruvate kinase (PK) and malic enzyme (ME) to Pyr (VPK+ME), and substrate 
flux to Pyr (VLDH). Multiple substrates, including lactate (Lac) and amino acids, shuttle through Pyr 
to the CAC; thus, VLDH encompasses all non-PEP derived, unlabeled sources of anaplerotic flux to 
the CAC.  
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Table 4.1  
Metabolic network model for in vivo metabolic flux analysis.  
 
Anaplerosis and Gluconeogenesis 
VEndoRA G6P (AaBbCcDdEeFfg) → Gluc.ext (AaBbCcDdEeFfg) 
VPYGL Glycogen (AaBbCcDdEeFfg) + H 
(h)  
→ G6P (AaBhCcDdEeFfg) + H (b) 
VGPI F6P (AabBCcDdEeFfg) + H (h)  → G6P (AbBhCcDdEeFfg) + H (a) 
VALDO DHAP (CchBAab) + GAP 
(DdEeFfg)  
→ F6P (AabBCcDdEeFfg) + H (h) 
VGAPDH BPG (ABbCcd) + H (e) + H (f)  → 0.5*GAP (AfBeCcd) + 0.5*DHAP (AefBCcd) + H (b) 
VGK Glycerol (AaeBbCcd) + H (f)  → 0.5*DHAP (AfeBCcd) + 0.5*GAP (AeBfCcd) + H (a) + H 
(b) 
VENO PEP (ABCcd) + H (b)  → BPG (ABbCcd) 
VPK+ME PEP (ABCab) + H (c)  → Pyr (ABCabc) 
VPC Pyr (ABCcde) + CO2 (D) + H (f) + 
H (g)  
→ 0.5*Oac (ABCfgD) + 0.5*Oac (DCBfgA) + H (c) + H (d) 
+ H (e) 
VPCK Oac (ABCabD)  → PEP (ABCab) + CO2 (D) 
VLDH Lac (ABbCcde) → Pyr (ABCcde) + H (b) 
Citric Acid Cycle 
VCS Oac (ABCcdD) + AcCoA (EFfgh)  → Cit (DCcdBFfgEA) + H (h) 
VIDH Cit (ABabCDcdEF) + H (e)  → Akg (ABCeaDcdE) + H (b) + CO2 (F) 
VOGDH Akg (ABCabDcdE)  → SucCoA (BCabDcdE) + CO2 (A) 
VSDH SucCoA (ABabCcdD) + H (e) + H 
(f) 
→ 0.5*Oac (ABCefD) + 0.5*Oac (DCBefA) + H (a) + H (b) 
+ H (c) + H (d) 
Infusates 
VINF Gluc.inf (AaBbCcDdEeFfg) → Gluc.ext (AaBbCcDdEeFfg) 
HINF H.inf (a) → H (a) 
HSINK H → Sink 
VPCC PropCoA (ABabCcde) + CO2 (D)  → SuccCoA (ACcdBabD) + H (e) 
The 19 reaction network model used for in vivo metabolic flux analysis, depicted in Figure 4.1, 
tracks both carbon (uppercase letters) and hydrogen (lowercase letters) atom transitions through 
the citric acid cycle and gluconeogenesis (Table A1). Infusion is indicated by .inf. Transport out of 
the liver is indicated by .ext. CO2 is unbalanced in the model because free transfer into or out of the 
system is assumed. Some metabolites have hydrogen atoms that are biochemically equivalent. The 
carbon positions of the equivalent hydrogen atoms are detailed in Table A2.  
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Table 4.2  
Metabolites with equivalent hydrogen atoms.  
 
Metabolite 
Carbon 
Position 
AcCoA 2 
Lactate 3 
PropCoA 3 
Pyr 3 
 
 
 
 
Figure 4.2  
The dependence of each flux estimate on isotopomer measurements. The heatmap shows the 
fractional contribution of mass isotopomers from each glucose fragment ion (top) to flux estimates 
(left).  
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Proof-of-concept: [U-13C3]-propionate infusion rate study 
Mice were placed in one of three [U-13C3]-propionate infusion groups and fasted 
15.5 hours. The experimental time course (Figure 4.3A) began when a 40 µL baseline 
arterial plasma sample was collected at 125 minutes. 2H2O and [6,6-2H2]-glucose venous 
administration was the same across infusion groups. A bolus of 2H2O was administered to 
all mice at 120 minutes to achieve a 4.5% 2H enrichment of body water. An 80 mg·kg-1 
prime of [6,6-2H2]-glucose was also given at -120 minutes. Following the prime, [6,6-
2H2]-
glucose was continuously infused at 0.8 mg·kg-1·min-1. At 0 minutes, mice in the standard 
infusion group received a 108.9 mg·kg-1 prime of [U-13C3]-propionate followed by a 
continuous infusion at 5.4 mg·kg-1·min-1. Mice in the one-half infusion group received half 
of the standard [U-13C3]-propionate dose per kilogram (54.5 mg·kg
-1 prime and infusion 
at 2.7 mg·kg-1·min-1). Accordingly, mice in the one-fourth infusion group received a 
quarter of the standard [U-13C3]-propionate dose per kilogram (27.2 mg·kg
-1 prime and 
infusion at 1.4 mg·kg-1·min-1). Plasma samples were collected from the arterial line at 90, 
100, and 110 minutes after approximately 19 hours of fasting. 
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Figure 4.3 
The experimental timecourse. (A) Experimental timeline. A 40 µL baseline plasma sample was 
taken from each mouse at 125 minutes. At 120 minutes, a bolus of 2H2O was administered, and 
the 0.8 mg/kg/min infusion of [6,6-2H2]-glucose was initiated with an 80 mg/kg prime. At 0 
minutes, the 5.4 mg/kg/min infusion of [U-13C3]-propionate was initiated with a 108.9 mg/kg prime 
for the standard infusion group, as shown. Accordingly, the one-half infusion group received a 
54.5 mg/kg prime followed by a continuous infusion of 2.7 mg/kg/min [U-13C3]-propionate. The 
one-fourth infusion group received a 27.2 mg/kg prime followed by a continuous infusion of 1.4 
mg/kg/min [U-13C3]-propionate. 50 µL isotopic steady state plasma samples were taken at 90, 100, 
and 110 minutes. Note the break in the timeline between 120 and 0 minutes. (B) The average 
blood glucose measurements taken over the time course for the mice in the standard (triangle, solid 
line; n=7), one-half (circle, dashed line; n=8), and one-fourth (square, dotted line; n=8) infusion 
groups. Note the break in the x-axis between 125 and 25 minutes.  
 
Blood glucose measurements were taken throughout the experimental time course. 
No significant differences in blood glucose were observed among the [U-13C3]-propionate 
infusion groups (Figure 4.3B). Ten minutes after the administration of the [U-13C3]-
propionate prime, a 14-20% increase in blood glucose was observed in all infusion groups. 
Thirty minutes later, blood glucose had returned to pre-prime levels (Figure 4.3B). The 
similarity in blood glucose throughout the time course suggests that the propionate infusion 
rate does not significantly alter hepatic glucose production.  
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Plasma glucose samples collected at 125, 90, 100, and 110 minutes (Figure 4.3A) 
from each mouse were analyzed by GC-MS. Baseline samples collected at 125 minutes 
produced MIDs that matched the theoretical distribution expected based on the natural 
abundance of stable isotopes. For example, the m/z 301 fragment, which retains all of the 
carbon and hydrogens from the parent glucose molecule (Figure 1.1), had less than 0.5% 
RMSE relative to its theoretical MID. Compared to baseline, m/z 301 fragment ions from 
samples collected at 90, 100, and 110 minutes showed a significant decrease in the relative 
abundance of the unlabeled (M+0) mass isotopomer (Figure 4.4A-C). In all infusion 
groups, the average MID was unchanged from 90 to 110 minutes, confirming that isotopic 
steady state had been achieved (Figure 4.4A-C).  
 
 
Figure 4.4 
Relative isotopomer abundances over the experimental timecourse. Average relative 
abundance of m/z 301 isotopomers at baseline (125 minutes) and isotopic steady state (90, 100, 
and 110 minutes) for mice in the (A) standard (n=7), (B) one-half (n=8), and (C) one-fourth (n=8) 
infusion groups. The y-axis shows the relative uncorrected abundance of each isotopomer detailed 
in the legend from M+0 (unlabeled, m/z 301) to M+4 (m/z 305). Note the break in the x-axis.  
 
The isotopic steady state MIDs showed [U-13C3]-propionate dose-dependent trends 
in enrichment (Figure 4.5A-F). In all glucose fragments analyzed (Figure 1.1), the one-
fourth infusion group showed the highest average abundance of unlabeled (M+0) 
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isotopomers and the standard infusion group showed the lowest average abundance of 
unlabeled (M+0) isotopomers. Because the 2H2O bolus was the same for all infusion 
groups, the relative abundance of the M+1 isotopomers that result from single 2H 
incorporation are not significantly different. However, the abundance of higher mass M+2 
to M+4 isotopomers trend with the [U-13C3]-propionate infusion rate. In all fragments, the 
relative abundance of M+2 to M+4 isotopomers is highest in the standard infusion group 
and lowest in the one-fourth infusion group. For example, the m/z 301 fragment shows that 
glucose from the standard infusion group was 40% unlabeled (M+0) and 60% enriched 
with 2H and 13C isotopes, while the one-half infusion group was 50% enriched and the one-
quarter infusion group was 40% enriched (Figure 4.5E). 
 
 
Figure 4.5 
Comparison of isotopic enrichment levels to [U-13C3]propionate dose. Comparison of mean 
isotopic steady state mass isotopomer distributions among standard (black bars; n=7 mice), one-
half (striped bars; n=8 mice), and one-fourth (white bars; n=8 mice) infusion groups for six glucose 
fragments (Fig. 1B): (A) m/z 145; (B) m/z 173; (C) m/z 259; (D) m/z 284; (E) m/z 301; (F) m/z 
370. The y-axis shows the relative uncorrected abundance of each isotopomer detailed on the x-
axis, where M+n refers to the mass shift from the unlabeled state.  
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Figure 4.6 
Comparison of flux estimates among infusion groups. (A) Comparison of model-estimated 
fluxes among infusion groups: standard (black bars; n=7 mice); one-half (striped bars; n=8 mice); 
one-fourth (white bars; n=8 mice). The MFA results for the three isotopic steady state samples were 
averaged to obtain one representative set of values for each mouse. The bars represent the mean of 
the biological replicates, and the error bars show the standard error of the mean. VGK and VENOL are 
reported in hexose units. One-way ANOVA indicated at least one mean was different at VPYGL, VGK, 
VCS, VPCC, and VSDH. Tukey-Kramer was then used for pairwise comparisons. Letters above the bars 
indicate statistically separated groups. (B) Visualization of the 95% confidence interval (CI) around 
the estimates for VLDH obtained for one representative mouse in the standard, (C) one-half, and (D) 
one-fourth infusion groups. The solid line depicts the lack of model fit to the data, measured by the 
sum of squared residuals (SSR), as a function of the VLDH flux value. The model-determined optimal 
point occurs where the SSR is minimized. The VLDH flux was varied in each direction away from 
the optimal point while adjusting the remaining fluxes to obtain a new constrained minimum. The 
95% confidence interval is determined by the points where the solid line intersects with the 95% 
confidence threshold (dotted line). 
 
The flux of [U-13C3]-propionate into the citric acid cycle, VPCC, showed a 
significant, infusion rate-dependent trend (Figure 4.6A) that is consistent with the 
differences in the relative abundance of higher mass isotopomers in the derivative 
fragments (Figure 4.5A-F). The flux through VPCC was linearly correlated with the infusion 
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rate (R2=0.9981). Other fluxes in the citric acid cycle, VCS and VSDH, were also significantly 
correlated with the [U-13C3]-propionate infusion rate (Figure 4.6A). These trends suggest 
[U-13C3]-propionate infusion enhances flux through the citric acid cycle.  
Flux into gluconeogenesis, VENOL, was the same for all infusion groups (Figure 
4.6A). While some infusion rate-dependent trends were observed in the citric acid cycle 
fluxes, carbon entered gluconeogenesis at the same rate among all infusion groups, 
regardless of the [U-13C3]-propionate infusion rate. Consistent with the blood glucose 
measurements (Figure 4.3B), the rate of endogenous glucose production (VEndoRA) was the 
same for all infusion groups. 
The rates of glycogen depletion, VPYGL, and glycerol utilization, VGK, showed 
unexpected, [U-13C3]-propionate infusion rate-dependent trends (Figure 4.6A). All of the 
mice were fasted 19 hours, and therefore, we expected glycogen stores to be completely 
depleted. Therefore, we hypothesized that the apparent increase in VPYGL flux at lower 
infusion rates was a model artefact that emerges due to a reduction in the [U-13C3]-
propionate contribution to glucose enrichment. Simulations in INCA confirmed that the 
model-estimated values for VPYGL and VGK were inversely correlated. For example, fixing 
the VPYGL flux to zero in the model resulted in a corresponding increase in the model-
estimated VGK flux, and vice versa. Higher mass (M+3 and M+4) isotopomers of glucose 
were formed from the condensation of a 13C-labeled triose-phosphate intermediate (derived 
from CAC) with an unlabeled triose-phosphate (potentially derived from glycerol). For 
many fragments, M+3 and M+4 isotopomers were reduced in the one-half infusion group 
and completely absent in the one-fourth infusion group (Figure 4.5). The low abundance 
of these high mass isotopomers likely contributed to the model’s inability to accurately 
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determine VGK. A similar issue was observed by Antoniewicz et al. (2) in their retrospective 
analysis of two previous in vivo [U-13C6]-glucose infusion studies, where decreased 
abundance of high mass isotopomers was implicated as the cause of poor flux identifiability 
in the study that used a lower tracer infusion rate. 
Flux estimates were highly reproducible across different mice within the same 
infusion group. This precision is reflected in the standard errors shown in Figure 4.6A. 
However, sensitivity analysis of the best-fit model estimates indicated a gradual loss of 
flux identifiability with decreasing infusion rate. The 95% flux confidence intervals for the 
samples in the standard infusion group were parabolic and narrow with a well-defined 
optimal point. One such confidence interval is visualized in Figure 4.6B for a representative 
sample in the standard infusion group. The model-predicted 95% confidence interval for 
VLDH had a lower limit of 0.99 and an upper limit of 2.72 µmol/min, closely bracketing the 
optimal value of 1.60 µmol/min. While still parabolic, the confidence intervals for the 
samples in the one-half infusion group were wider than those observed in the standard 
infusion group, with optimal points that were less well defined. In the example shown in 
Figure 4.6C for one representative sample in the one-half infusion group, the optimal VLDH 
value was 1.57 µmol/min and the 95% confidence interval ranged from 0.52 to 5.92 
µmol/min. Finally, the confidence intervals for the samples in the one-fourth infusion 
group were not parabolic. Instead, the confidence intervals were very long and flat on one 
or both sides of the optimal point, which was poorly defined. For one representative sample 
in the one-fourth infusion group (Figure 4.6D), the optimal VLDH value was 2.42 µmol/min, 
the lower limit of the 95% confidence interval was 0.07 µmol/min, and the upper limit of 
the confidence interval was 1.06x105 µmol/min (off scale). The low glucose enrichment 
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(Figure 4.5) in the one-fourth infusion group, and to a lesser extent in the one-half infusion 
group, likely led to the loss in flux identifiability at lower infusion rates.  
The data from these studies supported the use of the standard prime and infusion 
rate. While some enhancement in the CAC flux was observed, the high levels of glucose 
enrichment and the narrow confidence intervals obtained on model-derived flux estimates 
together indicated that the standard dose was optimal for further studies.  
 
Proof-of-concept: Fasting study 
The mice in the standard infusion group, hereafter referred to as the long-term 
fasting group, had been fasted for 19 hours at the time isotopic steady state plasma samples 
were collected. To test the effect of fasting period on hepatic glucose production, mice 
were fasted 5.5 hours before the experimental time course was initiated, with the collection 
of a 40 µL baseline plasma sample at 125 minutes (Figure 4.3). The standard protocol, 
previously determined to be optimal, was used for tracer infusions. Plasma samples were 
collected from the arterial line at 90, 100, and 110 minutes after approximately 9 hours of 
fasting. These mice comprised the short-term fasting group. 
Blood glucose measurements were taken throughout the time course. At 125 
minutes, the short-term fasted mice had a significantly higher blood glucose level than the 
long-term fasted mice (Figure 4.7A), as expected. After the [U-13C3]-propionate prime was 
given at 0 minutes, a spike in blood glucose was observed in both the short and long-term 
fasted mice (Figure 4.7A). The increase in blood glucose was of a similar magnitude in 
both groups. Blood glucose was significantly different between groups from the beginning 
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of the time course to 90 minutes. The average blood glucose measurements from 100 to 
120 minutes were not significantly different between the groups (Figure 4.7A).  
  
 
Figure 4.7 
Comparison of blood glucose and enrichment levels between fasting groups. (A) Comparison 
of the average blood glucose measurements taken over the experimental time course for short 
(square marker, solid line; n=5) and long-term (circle marker, dotted line; n=7) fasted mice; *p < 
0.05. (B) The average mass isotopomer distributions for fragment m/z 301 from baseline (125 
minutes) and isotopic steady state (90, 100, and 110 minutes) samples from short-term fasted mice 
(n=5). (C) Comparison of the average relative abundance of m/z 301 isotopomers between the short 
(n=5) and long-term (n=7) fasted mice at isotopic steady state. At 90-110 minutes, the mice in the 
short-term group had been fasted approximately 9 hours, while the mice in the long-term group 
had been fasted 19 hours. For (B) and (C), relative abundance is shown uncorrected for each mass 
isotopomer from m/z 301 (M+0) to m/z 305 (M+4). 
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The glucose in the 125, 90, 100, and 110 minute plasma samples from the short-
term fasted mice was derivatized and analyzed by GC-MS. Like the long-term fasted mice 
(Figure 4.4A), the short-term fasted mice were at isotopic steady state during sample 
collection at 90, 100, and 110 minutes. The average MID for the m/z 301 fragment was 
unchanged from 90 to 110 minutes (Figure 4.7B). At isotopic steady state, the short and 
long-term fasted mice showed differences in stable isotope labeling. For example, the M+0 
isotopomer of the m/z 301 fragment was more abundant in the short-term than in the long-
term fasted mice (Figure 4.7C). 
The MIDs from the short-term fasting group were imported into INCA for MFA. 
The fluxes in the model (Figure 4.1) were estimated and compared to the average fluxes 
from the long-term fasting group (Figure 4.8). At isotopic steady state, the short-term group 
had been fasted 9 hours, while the long-term group had been fasted 19 hours. The absolute 
fluxes reported either with normalization to mouse weight (i.e., in units of µmol/min, 
Figure 4.8A) or without normalization (in units of µmol/kg/min, Figure 4.8B) show 
expected trends. The rate of glycogen breakdown, VPYGL, was significant in the short-term, 
9 hour fasted mice. However, after long-term fasting, glycogen stores were depleted and 
flux through VPYGL was negligible. Other carbon sources, including glycerol (VGK) and PEP 
(VENOL), were used exclusively by the long-term fasted mice for hepatic glucose production 
(Figure 4.8A-B). This shift becomes even more evident when fluxes are reported relative 
to VEndoRA (Figure 4.8C), consistent with the differences in enrichment observed in Figure 
4.7C. 
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Figure 4.8 
Effect of fasting time on fluxes. Comparison of model-estimated fluxes after 9 (white bars; n=5 
mice) and 19 (black bars; n=7 mice) hours of fasting (A) in µmol/min, (B) in µmol/kg/min, (C) 
relative to VEndoRA. VGK and VENOL are reported in hexose units. The MFA results for the three 
isotopic steady state samples were averaged to obtain one representative set of values for each 
mouse. The bars represent the mean of the representative sets, and the error bars show the standard 
error of the mean. The statistical comparison was performed by a Student’s t-test with equal 
variance; *p < 0.05. 
 
 
Effect of CO2 recycling on flux values 
 The base model (Table 4.1) was revised to allow 13CO2
 recycling in order to test 
assumption (E) described in Modeling hepatic glucose production in INCA. Two 
additional reactions were added: (1) a CO2 source reaction (CO2.source (A) → CO2 (A)); 
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(2) a CO2 sink reaction (CO2 (A) → CO2.sink (A)). In this revised model, CO2 is a 
balanced metabolite, and 13CO2 produced in the CAC or during pyruvate cycling can be 
fixed by PCC or PC.  Fluxes were estimated and fits were accepted as described above. 
Within each group, the average fit to the model improved, as indicated by a decrease in 
SSR compared to the base model (Table 4.3). The improvement in fit was most significant 
(≥50% decrease in SSR) for long-term fasted mice. While the simulated enrichment of the 
CO2 pool was not significantly different between the short-term and long-term fasted mice 
infused with the standard [13C3]propionate dose (Table 4.3), CO2 fixation was greater in 
the long-term fasted mice, allowing for a more significant change in MIDs and fit (Figure 
4.8-4.9). Because CO2 is produced during the conversion of [
13C3]propionate to succinyl-
coA, the enrichment of the CO2 pool trended with infusion rate (Table 4.3).  
CAC and pyruvate cycling fluxes changed when CO2 recycling was allowed. 
Differences in CAC-related fluxes among the three [13C3]propionate infusion groups 
became insignificant (Figure 4.9A), suggesting that the infusion rate may not significantly 
alter intermediary metabolism. As expected, the VPCC estimates showed an infusion rate-
dependent change (Figure 4.9A). Discrepancies in VGK and VPYGL were still apparent and 
related to low enrichment and poor flux identifiability in the one-half and one-fourth 
infusion groups (Figure 4.9A). Qualitatively, the trends observed between the short- and 
long-term fasted mice did not change when the data was fit to the revised model (Figure 
4.9B). 
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Figure 4.9 
The effect of CO2 recycling on flux estimates.  Comparison of model-estimated fluxes with CO2 
recycling (A) from long-term fasted mice in the standard (black bars; n=7), one-half (striped bars; 
n=8), and one-fourth (white bars; n=8) [13C3]propionate infusion groups and (B) from short- (white 
bars; n=5)  and long-term (black bars; n=7) fasted mice. MFA results within each group were 
averaged to obtain a representative set of values for each mouse. Data are presented as means ± 
SEM. VGK and VEnol are reported in hexose units. Infusion groups were compared by one-way 
ANOVA and Tukey-Kramer; letters above the bars indicate statistically separated groups. Fasting 
groups were compared using a t-test with equal variance; *p<0.05. 
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Table 4.3  
Effect of CO2 recycling on SSR and simulated CO2 enrichment. 
 
Fasting 
Period 
[13C3]propionate 
Infusion Rate 
SSR without 
CO2 Recycling 
SSR with CO2 
Recycling 
Simulated CO2 
Enrichment 
short standard 6.1 ± 0.8 4.5 ± 0.3 4.8 ± 0.7% 
long standard 26.2 ± 1.5 5.2 ± 0.8 5.2 ± 0.4% 
long one-half 18.9 ± 4.7 9.6 ± 4.3 4.2 ± 0.4% 
long one-fourth 6.3 ± 0.5 3.4 ± 0.3 2.3 ± 0.2% 
 
Simulated MIDs through the best-fit model were compared to the experimental MIDs, and SSR 
was calculated. The SSRs for the three isotopic steady state samples were averaged to obtain a 
representative value for each mouse. The table shows the mean of the representative SSRs ± SEM 
for each group fit to the base model (SSR without CO2 Recycling) or to the revised model that 
allowed CO2 recycling (SSR with CO2 recycling). The enrichment of the hepatic CO2 pool (i.e. 
the relative abundance of 13CO2) was simulated through the best-fit model for each mouse. Values 
are expressed as mean enrichment ± SEM. short/standard n=5; long/standard n=7, long/one-half 
n=8, long/one-fourth n=8. 
 
 
 
Validation: 2H2O and [6,6-2H2]glucose 
 One major advantage of the NMR-based MFA methodology is the ability to 
discriminate between 2H and 13C isotopes. The GC-MS-based method can measure the 
single mass shift associated with isotope incorporation, but the identity of the isotope 
cannot be determined with standard instrumentation. Our method relies on the model to 
deconvolute 2H and 13C contributions.  
 To test the model’s ability to determine 2H and 13C labeling, we combined 
simulation and experimental studies. We first performed a simulation study using the best-
fit model for each mouse in the short-term fasting group (n=5). [U-13C3]propionate was 
removed as a tracer from INCA, and the labeling through the best-fit model using only 
2H2O and [6,6-
2H2]glucose was simulated. The simulated MIDs were fit to the base model 
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(Figure 4.1). We expected that CAC fluxes would not be determinable because they were 
informed by 13C incorporation from [U-13C3]propionate. However, no fluxes in the model 
could be estimated with confidence. We hypothesized that the flux values could not be 
estimated accurately with VCS fixed. When fluxes were estimated relative to VEndoRa, CAC 
fluxes were not determinable but gluconeogenic fluxes could be estimated with good 
confidence from simulated data. The model was simplified to remove fluxes that could not 
be estimated accurately (Figure 4.10). VENOL, VGK, VPYGL, VEndoRa, and VINF were unchanged 
from the base model (Figure 4.1). In the base model, pyruvate enters gluconeogenesis by 
first being converted to Oac by PC and then to PEP by PCK. The carbon transfers involved 
in these reactions make their estimations impossible with only deuterated tracers. 
Therefore, a single pyruvate source, labeled VPC in Figure 4.10, was created by combining 
VPC and VPCK (Pyr (ABCcde) + H (f) + H (g) → PEP (ABCfg) + H (c) + H (d) + H (e)).    
 
Figure 4.10 
A simplified model for estimating gluconeogenic-related fluxes using deuterated tracers. The 
model has a single pyruvate source, VPC. The remaining reactions are identical to those shown in 
Figure 4.1.  
 
 The GNG-related fluxes VEndoRa, VPYGL, VGK, and VEnol were identical between the 
simulation study and the fasting study results (Figure 4.11). The combined pyruvate source 
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flux from the simulation study, VPC, was equal to the amount of pyruvate entering GNG by 
VPCK minus the amount of PEP converted to Pyruvate by VPK+ME from the fasting study. In 
all, the simulation study confirmed that GNG-related fluxes in a simplified model could be 
regressed accurately from experiments that only used 2H-labeled tracers.  
 
 
Figure 4.11 
Comparison of GNG-related fluxes between simulated and fasting study data. The x-axis 
shows GNG-related fluxes. The y-axis is absolute flux in µmol/kg/min. The measured data (blue 
bars) from the short-term fasting study is identical to that shown in Figure 4.8. The flux values in 
the measured – 3 tracer group were obtained by fitting MIDs to the base model (Figure 4.1). The 
simulated values (gray bars) were obtained by fitting simulated data, containing only 2H labeling, 
to a revised model (Figure 4.10). 
  
 
 For the experimental component of this study, eight mice were fasted as in the 
short-term group described in Proof-of-concept: Fasting study. The experimental 
timecourse was identical to Figure 4.3A except [U-13C3]propionate was not infused. Plasma 
samples collected at 90, 100, and 110 minutes confirmed that steady-state was reached 
(Figure 4.12). As expected, the enrichment levels were much lower in this study than in 
the fasting study, where all three tracers were used (Figure 4.7B).  
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Figure 4.12 
2H enrichment over the experimental timecourse. The mean ± SEM of the relative abundances 
of each m/z 301 mass isotopomer from M+0 to M+5 is shown at ‒125, 90, 100, and 100 minutes. 
The MIDs were corrected for natural abundance.   
 
The MIDs from this study show the expected M+1 and M+2 labeling patterns 
(Figure 4.13). Because 2H2O infusion enriches the body water pool by less than 5%, 
incorporation of more than one 2H onto a single glucose molecule is unlikely. The only 
M+2 isotopomers measured were from fragments that contain carbon six of glucose (Figure 
1.1). Therefore, the M+2 abundance reflects the infusion of [6,6-2H2]glucose.    
 The MIDs simulated through the best-fit model from the short-term fasting group 
were very similar to the measured MIDs (gray bars vs. orange bars, Figure 4.13). The 
percent difference in the relative abundance of M+0 ranged from 0.4 to 3.8% (Table 4.4). 
This result strongly suggests that the model accurately deconvoluted the 2H and 13C 
contributions. Based on the similarity in MIDs, we expected flux estimations to be similar. 
This hypothesis was supported by the results shown in Figure 4.14. All fluxes were 
estimated with high confidence.  
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Figure 4.13  
Comparison of simulated and measured MIDs. Corrected mean steady-state MIDs ± SEM for 
the simulated (n=5; gray bars) and measured (n=8; orange bars) groups.  
 
 
 
Figure 4.14 
GNG-related flux estimates from simulated and measured data. Corrected mean absolute flux 
values ± SEM (µmol/kg/min). The gray bars show flux estimates from simulated MIDs. The orange 
bars show flux estimates from measured MIDs.  
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 The reduced model (Figure 4.10) is overly constrained by the mass balance around 
hydrogen. To test this constraint, the flux of hydrogen into the system was increased in 
silico by reducing the enrichment of the deuterated water tracer by one-half or by one-tenth 
in INCA. Increasing the hydrogen flux significantly altered estimations of VGK for 
biological samples using only 2H tracers. When the hydrogen flux was adjusted to be twice 
the initial value, VGK was halved and other fluxes in the model compensated but were not 
significantly different (Figure 4.15). When the hydrogen flux was adjusted to be ten times 
the initial value, VGK was zero and additional compensation was observed (Figure 4.15). 
The same effect was not observed with simulated data without added error, suggesting the 
reduced model is very sensitive to measurement error. Adjusting the hydrogen flux had no 
effect on VGK in the full model using the standard infusion protocol. However, the 
dependence of VGK estimation on 
13C labeling data, observed in the propionate study (see: 
Proof-of-concept: [U-13C3]-propionate infusion rate study), is supported by this 
finding. The reduced model is therefore best-suited for simulation and validation studies, 
not for flux estimation from biological samples.  
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Figure 4.15 
Effect of hydrogen flux on the reduced model. Average ± SEM flux values from biological 
samples with the standard hydrogen flux into the system (gray bars), twice the normal hydrogen 
flux (blue bars), or 10 times the normal hydrogen flux (orange bars).  
 
13CO2 recycling could affect the M+1 pool of the simulated MIDs. Incorporation of 
13C 
from CO2 at VPC or VPCC (Figure 4.1) would cause a single mass shift that the base model 
would attribute to 2H incorporation. When MIDs were simulated from the best-fit model 
that included CO2 recycling (see: Effect of CO2 recycling on flux values), the simulated 
MIDs were in better agreement to measured MIDs, with percent differences in M+0 
ranging from 0.1 to 1.7% (Table 4.4).    
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Table 4.4 
Percent difference between simulated and measured MIDs with or without 13CO2 recycling. 
 
 M+0 percent difference (%) 
Fragment (m/z) Without CO2 recycling With CO2 recycling 
145 3.8 1.7 
173 0.7 0.1 
259 1.8 1.0 
284 1.4 0.4 
301 2.2 1.2 
370 3.0 1.6 
 
 
Conclusions and Future Directions 
 We hypothesized that six overlapping glucose derivative fragments (Figure 1.1) 
could provide sufficient information for flux analysis. The results of the studies above 
strongly support this hypothesis. Combined with mathematical modeling in INCA (Figure 
4.1), the measurements provided high-confidence flux estimations. 
 In the first study, different rates of [U-13C3]propionate were infused to determine 
the optimal infusion protocol. The standard rate used in NMR experiments was determined 
to be the best for the GC-MS-based methodology. Reducing 13C enrichment decreased the 
confidence of flux estimations (Figure 4.6). CAC-related fluxes trended with infusion rate, 
suggesting that [U-13C3]propionate infusion may affect intermediary metabolism. 
However, the rate of endogenous glucose production (VEndoRa) was not significantly 
different among the groups (Figure 4.6). The stable VEndoRa is also supported by the blood 
glucose measurements, which did not show an infusion rate-dependent change (Figure 
4.3B).     
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 The fasting study produced results (Figure 4.8) that were consistent with 
physiological expectations. Long-term fasting depleted glycogen stores, sending VPYGL to 
zero. Compared to the short-term fasting group, the long-term fasted mice relied more 
heavily on pyruvate, lactate, glucogenic amino acids, and glycerol as carbon sources for 
glucose. The absolute flux values and their precision were similar to NMR-based studies 
(61).  
 The base model (Figure 4.1) could be improved by allowing 13C recycling from the 
CO2 pool. When the model was adjusted to allow for CO2 recycling, fits, as measured by 
SSR, improved for all groups (Table 4.4). Differences in CAC fluxes reported in the 
infusion study became insignificant in the revised model, suggesting [U-13C3]propionate 
infusion may not significantly affect intermediary metabolism. Future studies measuring 
metabolic intermediate and amino acid labeling from tissue samples could further validate 
the methodology and support the inclusion of CO2 recycling in the model. Empirically 
measuring the enrichment of the CO2 pool, perhaps by measuring urea, could also support 
the addition of recycling to the model.  
 Simulated and experimental MIDs were closely matched in the 2H2O and [6,6-
2H2]glucose validation study (Figure 4.13). These results suggest that the model accurately 
assessed the contribution of 2H and 13C in the three tracer methodology, at least in short-
term fasted animals. Simulated data from a model that allowed for CO2 recycling was a 
better predictor of the measured data (Table 4.4), further supporting the inclusion of CO2 
recycling in the base model.  
 The GC-MS-based MFA methodology described in this chapter scales down the 
traditional NMR-based method. This scaled down method has higher throughput, lower 
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cost, and improved sensitivity. The extensive computation required can be simplified using 
a GUI designed for batch processing in INCA (APPENDIX D). For validation studies, we 
used the same tracers used in NMR. However, simulation studies show that confident flux 
estimates can be obtained with other tracer sets as well. The methodology described here 
can serve as a robust platform for the investigation of many biological questions.  
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CHAPTER V 
SUMMARY OF CONCLUSIONS 
 
 We hypothesized that the six derivative fragment methodology proposed by 
Antoniewicz et al. (4) could be used for positional enrichment of glucose from biological 
samples. The studies described in CHAPTER II supported this hypothesis. While the 
measurement errors associated with the MID measurements were more significant in 
biological samples, weighting the fragments by inverse error and reducing the number of 
isotopomers active in the model allowed for accurate positional enrichment estimations. 
GUI tools built in the MATLAB programming environment simplified and automated the 
complex computational steps, increasing the accessibility of the methodology.  
 We believed that the revised methodology validated in CHAPTER II had broad 
applicability within metabolic research. We successfully applied the methodology to 
investigate glucose cycling in isolated mouse islets in CHAPTER III. We showed the first 
evidence supporting significant rates of glucose cycling, regulated by G6pc2, in mouse 
islets. Future work will apply the methodology to investigate glucose cycling in human 
islets.  
 We hypothesized that the six glucose derivative fragments could provide sufficient 
information for MFA. Multiple studies described in CHAPTER IV supported this 
hypothesis. The validated methodology will be used in future studies to quantify metabolic 
fluxes in mouse models of human disease.  
The novel methodology described in this thesis used an interdisciplinary approach 
to accurately characterize the positional enrichment of stable isotopes on glucose. The 
combination of chemical and computational methods to assess positional enrichment 
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represented a major departure from standard NMR-based approaches. The method has the 
potential to act as a framework for the development of novel strategies for positional 
enrichment analysis of other metabolites of interest.  
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APPENDIX A 
USER MANUAL FOR THE INTEGRATION GUI 
A INTRODUCTION 
integrate_gcms is a MATLAB-based graphical user interface (GUI) designed to guide a 
user through the process of integrating gas chromatography (GC)-mass spectrometry (MS) 
data from stable isotope tracer experiments in order to obtain mass isotopomer distributions 
(MIDs) for user-defined metabolites of interest. Integration utilizes a fixed-width, 
adjustable baseline algorithm described by Antoniewicz et al. (1) and detailed in section F.  
B SYSTEM REQUIREMENTS 
 Windows 7 or later 
 MATLAB R2011a or later, including:  
‐ Bioinformatics toolbox 
‐ Statistics toolbox 
C GETTING STARTED 
C1 Installation 
The GUI is provided in a *.zip folder. Extract the folder to any directory. The folder should 
contain a function integrate_gcms.m and three folders: int_bin, int_help, and 
int_methods. 
C2 Launching the GUI 
Start MATLAB and change the working directory to the folder containing 
integrate_gcms.m. Type integrate_gcms into the Command Window and press enter to 
launch the GUI. The GUI (Figure A.1) can be resized as needed to fit your screen by using 
the maximize function or by grabbing the edge of the interface and dragging to adjust the 
width and/or height. 
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D GUI components 
D1 File list 
The user selects NetCDF data files to load using the file menu (D5.1) or by clicking the 
Add button (Figure A.2). The filenames are displayed in the 
listbox identified as D1 (Figure A.1). The first filename is 
highlighted after loading, and its chromatogram is displayed in the 
GUI axis (D2). Left-click any filename in the listbox to select a 
different file to visualize. The keyboard’s up and down arrows can 
also be used to quickly browse through the loaded data. The Clear 
button (Figure A.2) removes ALL of the loaded files from the GUI 
workspace. 
D1 
D3 
D5 
D6 
Figure A.1 
The launched GUI with major components identified. 
Figure A.2 
Loading and visualizing 
NetCDF files. 
D1.1 
D2 
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Figure A.3 
The method panel allows the user to load and edit an existing method or create a new method. 
D1.1 Right-click menus 
Right-clicking on any filename reveals a secondary menu (Figure A.2) with additional 
options. Sample info… displays the meta data associated with that file, including the 
timestamp of the GC-MS collection, the sample name, and the listed GC-MS operator. 
Remove from list removes the selected file from the loaded data. Set peak parameters… 
reveals a new GUI panel that allows the user to manually edit the retention time, peak start, 
peak end, and baseline assigned by the algorithm (D4). 
D2 Chromatogram plot 
The GUI axis, identified as D2 in Figure A.1, displays the chromatogram for the selected 
file. The x-axis is time in minutes, and the y-axis is total ion abundance. Utilize the plot 
tools (D6) to investigate the chromatogram. Turn on selected ion traces in the method table 
(D3.3) to visualize the abundance of an ion range of interest and to identify metabolite 
peaks (Figure A.3). 
D3 Integration method panel 
 
 
 
 
 
 
D3.1 Button functions 
 Load Allows the user to select a *.m integration method file (also D5.1). 
D3.2 
D3.3 
D3.1 
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 Save Allows the user to save an integration method as a *.m file (also 
D5.1). 
 Clear Clears the loaded method from the GUI workspace. 
 Check Using the metabolite information defined by the user, the Check 
button finds the target metabolites, calculates the noise and the baseline, and 
then determines the peak start and the peak end (algorithm detail, F1). The peak 
start, peak end, and average baseline are displayed for the user as plot 
annotations following successful completion of Check (Figure A.3). 
Metabolites that are not found are returned with a retention time of zero. 
 Run The Run button sums the total ion counts between the peak start 
and peak end and subtracts the baseline for each metabolite (algorithm detail, 
F2). The integrated counts for each ion in the range are normalized, and the 
mass isotopomer distributions are written to a *.csv file (G4). 
D3.2 Metabolite pull-down menu, Name, and Retention Time 
The pull-down menu displays all of the defined metabolites. Selecting a metabolite displays 
its information in the method panel. The name of the metabolite can be changed in the 
Name edit textbox. The  button can be used to remove the selected metabolite from the 
integration method. The user can refine each metabolite’s retention time using the 
Retention Time (min) edit textbox; this information is key to ensure that the GUI can find 
the target metabolite in each loaded file. 
D3.3 Method table 
The method table has 6 columns: 
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 Main Ions  The main ions expected in the selected metabolite. Each 
main ion is defined as a range to account for stable isotope labeling (e.g. m/z 
173-180). This information is used to find the target metabolite; as such, 
defining more than one main ion improves the ability of the algorithm to find 
the metabolite. Each main ion range must have a defined relative intensity (Rel 
Intensity). 
 Show Ion Trace Check the box beside a defined Main Ions cell to visualize 
the abundance of the ions in the selected range (axis, Figure A.4). 
 Rel Intensity The estimated relative intensity of each main ion. Every 
defined main ion range must have a defined relative intensity. This information 
is used to find the target metabolite. 
 Integration Range(s) After the metabolites are found with peak start, peak 
end, and baseline defined, the ion ranges provided in this column define which 
MIDs are desired by the user. This column is entirely separate from the Main 
Ions column, and the ranges defined can be different from the ranges used for 
target identification. 
 Formula  The chemical formula of the fragment defined in each 
integration range. This information is optional, but is necessary to output the 
theoretical MID for an unlabeled fragment and to correct for natural abundance 
(D5.2). 
 Labels  The maximum possible labeling if all of the fragment atoms 
are labeled. For example, if a 13C stable isotope tracer is used, and the fragment 
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has four carbons, then the Labels column should read C4. This information is 
optional, but is necessary to correct for natural abundance (D5.2). 
D4 Edit peak parameters panel 
This panel is accessible from the Options menu (Manually set peak parameters… D5.2) 
or by right-clicking on any filename in the listbox and selecting Set peak parameters… 
(D1.1 and Figure A.2). The panel covers the Method table until the user presses the Done 
button (red box, Figure A.4). Following Check (D3.1), the peak start, peak end, and 
baseline is defined for each file and all metabolites. The user can view and manually edit 
the algorithm-determined values if they appear to have been set in error. All edits are 
immediately applied and visualized on the chromatogram. 
D4.1 Visualize and Adjust Baselines 
The adjustable baseline algorithm calculates a baseline for every ion in each integration 
range. If the option to Calculate baseline for each ion (Figure A.7; D5.2) is checked 
(default), then the  button beside Avg Baseline in the peak parameters panel (Figure 
A.4) is enabled. Clicking this button launches a small interface that allows the user to view 
and adjust any of these baselines (Figure A.5). If the Calculate baseline for each ion 
(Figure A.7; D5.2) is not checked, then the integration function will use the average 
baseline shown in the panel to perform baseline subtraction. 
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Figure A.4 
The peak parameters (highlighted by a red box) can be viewed and edited manually by the 
user in the panel accessible from the Options menu or by right-clicking on a filename in the 
listbox. 
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Figure A.5 
All calculated baselines can be visualized 
and edited in the Visualize and Adjust 
Baselines interface. 
 
 
 
 
 
 
 
 
 
D5 Menu functions 
D5.1 File Menu (Figure A.6) 
 Load data… Allows the user to select 
one or more NetCDF files containing GC-
MS data for integration (also D1). 
 Load method… Allows the user to select 
a *.m integration method file (also D3.1). 
 Save method… Allows the user to save an integration method as a *.m file 
(also D3.1). 
 Export data to workspace Sends the loaded data formatted as a 
structure array and named NetCDF_data (G1) to the Command Window in 
MATLAB; the user can then edit the data, create plots, or save. 
 Import data from workspace Imports the structure array called 
NetCDF_data to the GUI workspace. 
Figure A.6 
The File menu. 
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D5.2 Options Menu (Figure A.7) 
 
 Set find peaks options…  In a new interface (Figure A.8), allows the 
user to edit the settings used to calculate noise and the baseline as well as to 
edit the algorithm used to find the peak start and the peak end (see F1). 
 Manually set peak parameters… Allows the user to edit the baseline, 
peak start, and peak end values assigned to a given metabolite in a single file 
(also D1.1). 
 Calculate baseline for each ion  Implements an adjustable baseline 
algorithm for baseline subtraction; by default, this option is checked. 
 Natural abundance correction  Uses tools described by Fernandez et 
al. (23) to correct mass isotopomer distributions for natural abundance; by 
default, this option is unchecked. 
 Integration outputs… Allows the user to select the desired outputs of 
integration; by default, *.csv is checked, but the user can also elect to output 
the data as a MATLAB *.mat file. 
 
Figure A.7  
The Options menu. 
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D6 Plot Toolbar 
 Note: hover over any icon on the plot toolbar to get the name of the tool. 
  Zoom in Turns the cursor into a magnifying glass. Left-click to zoom 
in, or hold down the left mouse button and draw a box to magnify a specific 
region of the plot. Right-click within the axis to open an options menu that 
allows for horizontal or vertical zooming. 
  Zoom out Turns the cursor into a magnifying glass. Left-click once to 
zoom out or double-click to reset the plot. Right-click within the axis to open 
an options menu that allows for horizontal or vertical zooming. 
Figure A.8 
The Find Peaks Options interface allows the user to 
adjust the settings used in the algorithm to calculate 
noise and the baseline.  
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  Pan  Turns the cursor into a hand. Grab within the plot by holding 
down the left mouse button, then drag to pan through the plot. 
  Data cursor The data cursor can be placed on the chromatogram to 
obtain exact x and y values for the selected point. 
  Brush/select data tool Use the brush to make annotations to the 
plot. 
  Legend on/off Turns the plot legend on or off. 
  Fill axis Resets all zooming and fills the axis with the plot. 
  Redraw plot annotations Upon zooming, peak annotations are 
obscured. This tool redraws the annotations on the plot. 
  Remove SICs Removes all selected ion chromatograms from the 
plot and unchecks all Show Ion Trace boxes (D3.3). 
  Open GC-MS scan   Opens the selected data file in a new 
window, allowing the user to review the MS scans in full (D6.1). 
  Open help document Opens the *.pdf help document.  
D6.1 GC-MS Scan 
The highlighted file (D1) is opened in the gcms_scan window when the user clicks the 
corresponding menu button (D6). gcms_scan contains two axes. The top axis contains the 
full chromatogram. As in D2, the x-axis is retention time in minutes, and the y-axis is the 
total ion abundance. The bottom axis shows the MS scan at a user-selected timepoint. The 
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x-axis shows the ion values (m/z), and the y-axis shows total ion abundance. Both the top 
and bottom axes can be manipulated with zoom, pan, and cursor tools, as described in D6. 
Two additional plot tools are present: 
  View ion traces Opens an input dialog box wherein the user can type 
specific ion (m/z) values to view the trace on the chromatogram (e.g. blue line, 
Figure A.9).  
  View MS Turns the cursor into crosshairs, allowing the user to select 
a specific point on the chromatogram to view the full MS scan (e.g. the full MS 
scan at 9.54 minutes is shown in Figure A.9, bottom panel).  
  
 
Figure A.9 
The gcms_scan window allows the user to review the full MS scan at any timepoint in the 
chromatogram. 
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E STEP-BY-STEP GUIDE 
1. Load GC-MS data in NetCDF format by clicking the Add button or from File > 
Load data… (D1 or D5.1) 
a. The listbox will populate with the loaded filenames, and the chromatogram 
for the first filename in the list will display in the axis. 
2. Load a saved *.m integration method by clicking the Load button in the 
Integration method panel (D3.1) or from File > Load method… (D5.1) 
a. For the format of the integration method file, refer to section G2. 
b. To create a new method, refer to section G3. 
3. For each target metabolite, refine the retention time 
a. Visualizing the main ion traces (D3.3) and the plot tools (D6) can be used 
to identify the metabolite peak’s retention time. 
4. Click the Check button (D3.1) to command the GUI to locate the target metabolites 
in each loaded file. 
5. Browse through the files in the listbox to verify that the target metabolite(s) were 
properly defined by the GUI. 
a. If needed, manually edit peak parameters set in error (D4). 
6. Click the Run button (D3.1) to integrate with respect to the ranges defined in the 
method (D3.3) and output a *.csv file with the MIDs. 
a. For an explanation of the output file, refer to section G4. 
7. Save the integration method (D3.1 or D5.1). 
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F ALGORITHM DETAIL 
F1 Defining a metabolite peak 
A press of the Check button (D3.1) commands the GUI to find a GC-MS peak 
corresponding to each defined metabolite. The Check function returns the retention time 
of the metabolite peak, the peak start and peak end, and the baseline. 
F1.1 Finding the Metabolite 
The algorithm uses the Main Ions and the estimated Rel Intensity defined by the user in 
the method table (D3.3) to locate the metabolite. The function calculates the probability, 
p1, that the metabolite peak is at a given time value, T, based on the ratio of the relative 
intensities of the main ions, MainIonsRelInt. Then, the function calculates the 
probability, p2, that the metabolite peak is at a given time value, T, based on the retention 
time, RetTime, provided by the user. The most likely timepoint, x, is based on the 
abundances of the selected ions in the Main Ions range, sum(sim), multiplied by p1 and 
p2.  
%  Determine most likely location of peak based on relative peak values  
K = nMainIons*0.1; 
p1 = (sum(abs(relsim-repmat(MainIonsRelInt,1,nT)))/K+1).^(-2); 
 
%  Determine most likely location of peak based on retention time  
K = 0.05; % minutes 
p2 = normpdf(T-RetTime,0,K); 
 
%  Determine most likely location of metabolite peak 
x = sum(sim).*p1.*p2;  
idx = find(x==max(x));  
idx = idx(1);  
timepoint = T(idx); 
 
F1.2 Calculating the noise 
The sum of the metabolite’s Main Ions is defined as the variable cnts. A built-in 
smoothing function, mssgolay (Figure A.10), is used to smooth cnts, and the 
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smoothed data is defined as c. The median of the difference between cnts and c, 
multiplied by the Noise multiplier (D4 and Figure A.8; the default multiplier is 1.8), is 
equal to noise. 
%  Smooth out data 
c = mssgolay([1:1:length(cnts)]',cnts'); 
 
% Estimate average noise-intensity or use the minimum noise level of 10  
NoiseLB = 10; 
noise = max(NoiseLB,options.noise_mult*median(abs(c-cnts))); 
 
 
 
 
 
 
 
 
F1.3 Identifying the baseline index and calculating the average baseline 
The scan numbers where cnts<=noise is set as the baseline index. The index values 
that are nearest to the metabolite peak, defined as the variable base, are used to calculate 
the average baseline, bsln. The average baseline is multiplied by a baseline multiplier, 
options.bsln_mult (D4 and Figure A.8; the default multiplier is 1.0). Note: the same 
index, base, is used to calculate the average baseline for every ion in the ion range, using 
each ion’s average abundance over the index. 
 
Figure A.10 
An example of smoothing the raw, summed selected ion chromatogram using mssgolay. 
 91 
 
% Set average baseline 
bsln = options.bsln_mult*mean(cnts(base)); 
 
F1.4 Defining the peak start and peak end 
From the peak maximum estimated to occur at timepoint, the function moves down, 
one scan at a time in a while loop, until the intensity of c is at noise times a multiplier, 
options.lb_mult (D4 and Figure A.8; the default multiplier is 10), and the change in 
intensity from scan-to-scan is greater than noise times a multiplier, options.lb_inc 
(D4 and Figure A.8; the default is 2). The point where the while loop is satisfied is set as 
the peak start. The same protocol is followed to set the peak end, except the function moves 
up, one scan at a time in a while loop until the conditions are satisfied. 
F2 Integration 
For each Integration Range defined in the method table (D3.3), a MID is calculated. The 
integration range is set as the variable SIM. The summed counts for each ion in SIM 
between peak start and peak end are calculated as simCnts. The baselines are subtracted 
from each ion’s simCnts, and the total integrated counts are calculated by taking the sum. 
The counts are then normalized to one, by convention. 
 
%  sum MS data between peak start and end  
sumMS = nansum(MS(peak(1):peak(2),:)); 
 
%  calculate total ion counts 
simCnts = sumMS(:,SIM(n,1):SIM(n,2)); 
 
%  correct for baseline by subtraction  
simCntsCorrected = max(0, simCnts-bsln); 
 
%  calculate total integrated counts 
tc = sum(simCntsCorrected); 
 
%  normalize counts to 1 
x = simCntsCorrected'/sum(simCntsCorrected)]; 
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G ADDITIONAL INFORMATION 
G1 MATLAB structure array: NetCDF_data 
NetCDF_data is a 1xn structure array, where n is the number of NetCDF files loaded 
into the GUI workspace. Each entry has 10 subfields (Table A.1): 
 
Table A.1  
Description of NetCDF_data subfields. 
 
Subfield Description 
filename NetCDF filename in a string, e.g. ‘00201004.cdf’ 
RT The time values, in minutes, in a tx1 matrix 
TIC The total ion counts corresponding to each time in RT; a tx1 matrix 
SIC 
The ion counts for each ion at each time in RT; an mxt matrix, where m is 
the ion mass. Unless the 
 collected data exceeds m/z 500, the SIC is by default 500xt 
info 
The metadata included in the file. Subfields within info: netcdf_stamp 
with the collection timestamp, 
 sample_name, operator, time (corresponds to t), and scans 
timepoints 
The time value corresponding to the maximum of each metabolite peak; a 
1xp matrix, where p is the 
 total number of metabolites in the integration method 
peak_start 
The time value corresponding to the peak start for each metabolite peak; a 
1xp matrix 
peak_end 
The time value corresponding to the peak end for each metabolite peak; a 
1xp matrix 
baseline 
The subfield SIM contains the baseline for each ion in the integration 
range for each metabolite 
avg_baseline The average baseline for each metabolite peak; a 1xp matrix 
  
 
 
G2 Format of an integration method file 
The *.m integration method file must be defined as a function called MSLib. Each 
metabolite in the function is defined in a structure array as follows: 
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function MSLib=Aldo_method() 
MSLib = struct('Name',{},        
'RetTime',{},'MainIons',{},'MainIonsRelInt',{},'SelectedIons',{}, 
'SelectedIonsFormula',{}, 'SelectedIonsLabeled',{}); 
Item.Name = 'Aldo'; 
Item.RetTime = 12.06; 
Item.MainIons = [173,178; 259,265; 284,289; 370,376]; 
Item.MainIonsRelInt = [100; 24; 12; 14]; 
Item.SelectedIons = [173,178; 259,265; 284,289; 370,376]; 
Item.SelectedIonsFormula = {'C8H13O4'; 'C12H19O6'; 'C13H18O6N'; 'C17H24O8N'}; 
Item.SelectedIonsLabeled = {'H3'; 'H4'; 'H3'; 'H4'}; 
MSLib(end+1) = Item; 
 
A new metabolite can be added within the GUI (G3) or directly to the end of the method 
*.m file, e.g.:  
Item.Name = 'New Metabolite'; 
Item.RetTime = 8.52; 
Item.MainIons = [210,218; 341,350]; 
Item.MainIonsRelInt = [100; 70]; 
Item.SelectedIons = [210, 218]; 
Item.SelectedIonsFormula = {'C17H24O8N'}; 
Item.SelectedIonsLabeled = {'H3'}; 
MSLib(end+1) = Item; 
 
The format must be exact to ensure proper loading. Item.Name is used in the Metabolite 
pull-down menu and written to the Name: edit textbox (D3.2). Item.RetTime is written 
in the Retention Time (min): edit textbox within the GUI (D3.2), and the remaining 
entries are written to specific columns in the method table (Table A.2, D3.3). 
Table A.2 
Correlation between MSLib subfields and method table columns 
 
MSLib subfield Method table column 
MainIons Main Ions 
MainIonsRelInt Rel Intensity 
SelectedIons Integration Range(s) 
SelectedIonsFormula Formula 
SelectedIonsLabeled Labels 
 
G3 Creating a new integration method 
1. The user must have knowledge of the target metabolite’s chemical properties, 
including what fragments are formed by ionization in the MS and the chemical 
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Figure A.11 
With Add new peak selected in the Metabolite menu, define the name of the new metabolite 
formula of the fragments of interest. This is best obtained using standards and other 
tools such as NIST libraries or AMDIS. 
2. In the GUI, define the name of the first target metabolite 
a. the Metabolite pop-up menu (D3.2) should read Add new peak until the 
Name is defined; then, the menu will populate with the new name (Figure 
A.11) 
 
 
 
 
 
 
3. Estimate the retention time for the target metabolite, and fill in the Retention Time 
(min) field (Figure A.11) 
4. In the Main Ions column in the method table (D3.3), set the ion ranges that will be 
used to identify the target metabolite 
a. At least two ranges are suggested for best results 
5. In the Rel Intensity column, estimate the relative intensity of each main ion range 
a. This process can be facilitated using plot tools. Turn on the ion traces for 
each main ion range and zoom in on the target peak. Use the data cursor 
tool to obtain the ion abundances. Set the most abundant ion range to 100, 
then scale the remaining ranges relative to this range. Accurate estimates 
facilitate proper identification of the metabolite by the GUI. 
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Figure A.12 
Estimating relative intensities of main ion ranges using GUI plot tools. 
b. For example (Figure A.12): 
i. m/z 173-178 is the most abundant range, so the Rel Intensity is set 
to 100. 
ii. m/z 370-376 has a maximum abundance of 2.961e+06; compared 
to m/z 173-178, this is approximately 60%. Therefore, the Rel 
Intensity is set to 60. 
iii. m/z 259-265 has Rel Intensity of approximately 50. 
iv.m/z 284-289 has Rel Intensity of approximately 30. 
 
 
 
 
 
 
 
 
 
 
6. In the Integration Range(s) column, identify the ion ranges for which MIDs are 
required. 
7. (Optional) Provide a chemical formula for the fragment defined by each integration 
range in order to obtain a theoretical MID and to correct for natural abundance 
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8. (Optional) Provide the number of atoms that could be labeled in the fragment by 
the stable isotope tracer; for example, if the fragment has five carbons that could 
be labeled, the Labels column should read C5. 
9. Add another metabolite to the method by selecting Add new peak from the 
Metabolite pull-down menu; follow steps 1-8. 
10. Save the method using the Save button (D3.1) or from File > Save method… 
(D5.1) 
 
G4 Understanding the output file 
The *.csv file that is created by the GUI can be opened in Excel in other spreadsheet 
software. The spreadsheet is separated into four sections: (1) Samples; (2) Retention 
Times (min.); (3) Total ion counts; (4) Mass isotopomer abundances.  
 
The Samples sections lists the sample names the user provided during the GC-MS run. 
The GCMS ID is the number assigned to each sample during the GC-MS run. For the 
Agilent system used to produce the data shown in Figure A.13, the ID number contains 
information on the sample number, replicate number, and injection number. For example, 
“702018” refers to sample #7, replicate #2, and injection #18.  
 
The Retention Times (min.) section lists the retention time for each metabolite in the 
integration method. The time reported occurs at the estimated maximum intensity (F1.1). 
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The Total ion counts section lists the total integrated counts for each ion range defined in 
the Integration Range(s) column in the method table (D3.3). While only the first ion is 
listed (e.g. Aldo 173 in Figure A.13), the total ion count is the sum of the abundances of all 
of the ions in the integration range from the peak start to the peak end, with the baseline 
subtracted (F2). 
 
The Mass isotopomer abundances section presents the MID for each metabolite and each 
integration range. In the final column, after the MIDs for all samples have been written, a 
column titled Theory is written (Figure A.13). This column contains the theoretical MID 
for an unlabeled sample with the chemical formula defined in the Formula column of the 
method table (D3.3). 
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Figure A.13 
Screenshot of integrate_gcms output file in Excel. 
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APPENDIX B 
USER MANUAL FOR THE POSITIONAL ANALYSIS GUI 
 
INTRODUCTION 
gpa is a MATLAB-based graphical user interface (GUI) designed to guide a user 
through the process of analyzing mass isotopomer distribution (MID) data from six distinct 
fragment ions in order to estimate the positional enrichment of deuterium (2H) on glucose. 
The methodology was adapted from Antoniewicz et al. (2). An overview of the method is 
shown in Figure 1.2.  
Sample glucose is derivatized through three different protocols. The chemically 
distinct glucose derivatives – glucose aldonitrile pentapropionate, glucose methyloxime 
pentapropionate, and glucose 1,2,5,6-di-isopropylidene propionate – elute at different 
times by gas chromatography and fragment into different ions by mass spectrometry. 
MIDs obtained from six separate ions are the required inputs into the GUI. These MIDs 
are used in a least squares (LSQ) regression to estimate the isotopic enrichment at each 
carbon position of the parent glucose molecule (Figure 1.2).  
The six MIDs are linearly combined in a single vector in MATLAB (MIDM). The 
theoretical MIDs expected for each of the 27 (or 128) possible hydrogen isotopomers of 
glucose are calculated based on natural isotope abundances and the atomic formula of each 
fragment. Theoretical MIDs are combined into a matrix, T. Multiplying T by a fractional 
contribution matrix, x, produces a vector of MIDs (MIDC) expected from the x-defined 
mixture of hydrogen isotopomers (Equation B.1). The LSQ regression minimizes the 
difference between MIDM and MIDC by manipulating x (Equation B.2). Therefore, the first 
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output of the computational method is an estimation of the relative abundance of each 
hydrogen isotopomer in the sample. Multiplying this output, x, by a transformation matrix 
that defines each hydrogen isotopomer in terms of zeros, representing unlabeled carbons, 
and ones, representing 2H-labeled carbons, produces a second output that quantifies the 
total 2H enrichment at each of the six carbon positions of glucose.   
𝑀𝐼𝐷𝐶 = 𝑇 × 𝑥 (B.1) 
min ∑(𝑀𝐼𝐷𝐶 − 𝑀𝐼𝐷𝑀)
2 (B.2) 
 
SYSTEM REQUIREMENTS 
 Windows 7 or later 
 MATLAB R2011a or later, including:  
‐ Bioinformatics toolbox 
‐ Statistics toolbox 
 
OPTIONAL SOFTWARE 
 integrate_gcms  
‐ to obtain accurate MIDs from raw GC-MS data 
‐ available from the Young lab 
 Isotopically Nonstationary Compartment Analysis (INCA) (77) 
‐ provides a secondary method for positional analysis for low enrichment 
experiments 
‐ available from http://mfa.vueinnovations.com/ 
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GETTING STARTED 
Installation 
The GUI is provided in a *.zip folder. Extract the folder to any directory. The folder 
should contain a function gpa.m and three folders: gpa_bin, gpa_help, and gpa_test. 
Launching the GUI 
Start MATLAB and change the working directory to the folder containing gpa.m. 
Type gpa into the Command Window and press enter to launch the GUI (Figure B.1). The 
GUI can be resized as needed to fit your screen by using the maximize function or by 
grabbing the edge of the interface and dragging to adjust the width and/or height. 
 
 
 
Figure B.1 
The launched gpa GUI. The GUI is divided into four major sections. MIDs are loaded from *.csv 
files in a. MIDs are visualized in b. The active isotopomers in the model are adjusted in c. In d, the 
user runs the analysis on the loaded data.   
 
a
1 
b 
c 
d 
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STEP-BY-STEP GUIDE 
1. Obtain MIDs 
Accurate MIDs are necessary for the methodology to produce accurate enrichment 
estimates. Root mean squared error (RMSE), measured by comparing MIDs from n 
unlabeled samples (MIDM) to the theoretical MID (MIDT), should not exceed 1% for any 
of the six fragments (Equation B.3). Work by Antoniewicz et al. (1) determined that a 
fixed-width, adjustable baseline integration produces the most accurate MIDs. The Young 
lab’s integrate_gcms GUI utilizes this algorithm, and the output *.csv files are directly 
compatible with gpa. Example *.csv files are included in the gpa_test folder.  
RMSE = 𝑚𝑎𝑥 (√
∑ (𝑀𝐼𝐷𝑀 − 𝑀𝐼𝐷𝑇)
𝑛
𝑖=1
2
𝑛
) (B.3) 
 
2. Load MIDs 
Three separate *.csv files are loaded into the GUI. The MIDs for m/z 173, 259, 
284, and 370, obtained from the aldonitrile derivative of glucose, are loaded by clicking 
the Aldo button (Figure B.2). The MID for m/z 145 is loaded by clicking the Mox button. 
The MID for m/z 301 is loaded by clicking the DiO button. In addition to the MIDs, the 
GUI imports the sample name and GCMS ID numbers to help the user navigate the data. 
Injection replicates are automatically averaged, and the GCMS IDs for these replicates are 
combined (e.g. in Figure B.2, the combined GCMS ID 013[01,02][029,030] indicates that 
the vial in position #13 was tested twice in injections #29 and #30). If loading is successful, 
the loading buttons are disabled, and the sample names and combined GCMS IDs populate 
the GUI table (Figure B.2). 
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Figure B.2 
The GUI table is populated with sample names and ID numbers. In this example, the three 
files were loaded from the gpa_test folder. The A_test.csv file was loaded by the Aldo button. 
M_test.csv was loaded by clicking Mox. The DiO button was used to load D_test.csv. 
 
3. View MIDs 
The GUI axes display the MIDs for each of the six ions (Figure B.3). The y-axes show 
relative ion abundance. The x-axes show the isotopomer distribution from an unlabeled 
(M+0) to fully labeled (M+n) state. The active sample has a + in the first column of the 
GUI table (e.g. in Figure B.2, Standard1 is the active sample). To change the active 
sample, the user can click on any cell in that sample’s row (Figure B.2).  
 
Figure B.3 
The GUI axes display the sample MIDs for each fragment. In this example, the MIDs for Expt1 
from gpa_test are shown.   
 
4. Add weights (optional) 
Work in the Young lab supports the use of weighting in order to produce the most 
accurate positional enrichment estimates. Each fragment is weighted based on the inverse 
of its RMSE (Equation B.3), which the GUI calculates from unlabeled control samples 
(Unlab Ctrl) checked by the user in the GUI table (Figure B.4).   
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Figure B.4 
Unlabeled control samples are used for weighting fragments in the LSQ regression. For the 
test case, Standard1 and Standard2 from gpa_test are checked as unlabeled control samples. 
 
5. Adjust active isotopomers in the model (optional) 
Because there are seven hydrogens on glucose, there are 128 possible hydrogen 
isotopomers in the full model. If assumptions can be applied to limit the number of active 
isotopomers, the analysis produces better enrichment estimates. All of the isotopomers 
with one 2H can be turned on by checking the M+1 box, two 2H by checking the M+2 box, 
etc. The fully unlabeled isotopomer is activated by checking M+0, and the fully labeled 
isotopomer is activated by checking the M+7 box (Figure B.5).  
 
 
Figure B.5 
The active isotopomers in the model can be adjusted by the user. The data collected for 
gpa_test was from an in vivo experiment that used infused 2H2O and [6,6-2H2]glucose to measure 
gluconeogenic flux and total glucose production, respectively. Based on the experimental design, 
we hypothesized that M+2 isotopomers would be improbable. Therefore, only M+0 and M+1 
isotopomers were active for this analysis.  
 
Specific isotopomers can be activated by clicking the Customize button. A custom dialog 
box appears after the Customize button is clicked (Figure B.6). The labeling state of each 
carbon, from the first carbon (C1) to the sixth carbon (C6), can be adjusted by the user. A 
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0 represents an unlabeled carbon. A 1 indicates a single 2H at that carbon position. C6 may 
also have a value of 2. To save the changes, the user must click the Return to GPA button 
(Figure B.6).  
 
 
Figure B.6 
The user can activate specific isotopomers in the model using Customize. Each carbon position 
is given a numerical value that indicates the number of 2H bound. For the test case, the only 
probable M+2 isotopomer in the model was from the [6,6-2H2]glucose tracer. Therefore, this single 
M+2 isotopomer, represented by the sequence 0 0 0 0 0 2, was added to the model.  
 
 
6. Run the LSQ regression 
By default, the LSQ Regression methodology is active. The user clicks the Run GPA 
button to begin the analysis (Figure B.7).  
 
Figure B.7 
A click of the Run GPA button initiates the analysis. 
 
7. Analyze the output files 
The LSQ regression produces two separate output files. The first file contains the 
fractional contribution values, x, for each sample (see INTRODUCTION). The first 
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column contains the numerical sequences for each active isotopomer in the model, using 
the same 0/1/2 representation detailed in step 5 (Figure B.8). 
 
The second output is the result of multiplying the fractional contribution values, x, 
by a transformation matrix as described in the INTRODUCTION. The Av column for 
each sample shows the average estimated enrichment (%) at each carbon position (Figure 
B.9). If many isotopomers are active in the model, this output provides a concise summary 
of enrichment. The best-fit data is plotted on the GUI axes to visualize the optimization 
(Figure B.10).  
 
 
Figure B.8 
The first output file contains the fractional contribution values for each isotopomer. Each 
isotopomer is represented by a numerical sequence. The six digits represent each carbon in glucose. 
A 0 indicates carbon with 1H bound, 1 with 2H bound, and 2 with two 2H bound (C6 only). The 
test case used a model with nine active isotopomers. Standard1 and Standard2 were unlabeled 
samples. The regression determined that 100% of the glucose in these standards was naturally 
labeled, as expected. The experimental samples, Expt1-Expt, have a significant abundance of [2-
2H]glucose and [5-2H]glucose, as expected for gluconeogenic experiments.  
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Figure B.9 
The second output file contains the total enrichment estimates (%) at each carbon position. 
 
 
Figure B.10 
After the analysis has completed, the minimized MIDs are plotted (fit) with the experimental 
values (data).  
  
 
8. Run positional analysis using INCA (optional) 
A complementary positional analysis can be performed by a secondary software 
program, INCA. At this time, analysis is constrained to low enrichment experiments that 
use the nine isotopomer model shown in Figure B.11. The output file (Figure B.11) details 
both isotopomer abundances and enrichment estimates. In addition, INCA evaluates the 
goodness-of-fit and reports a sum of squared residuals (SSR) value. The lower (LB95) and 
upper (UB95) bounds of the 95% confidence intervals are also reported.  
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Figure B.11 
The INCA output details isotopomer abundances (H1-H6), average enrichment values (D1-
D6), and an evaluation of the goodness-of-fit (SSR; 95% confidence intervals LB95 and 
UB95).  
 
9. Reset the GUI  
The user can press the Reset button at the top of the GUI to clear all loaded data 
(Figure B.12).  
 
 
Figure B.12 
The Reset button is used to clear all data from the GUI. 
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APPENDIX C 
DERIVATION OF GLUCOSE CYCLING EQUATION 
 
The model shown in Figure 3.1 defines the rate of glucose phosphorylation by 
glucokinase as v1, the rate of G6P hydrolysis by G6pc2 as v2, and the net glucose uptake as 
vnet. Based on this model, we derived simplified balance equations to describe the change 
in the MID of extracellular glucose over time as a result of glucose cycling. Let A represent 
the fractional abundance of the M+7 mass isotopomer of glucose after correction for natural 
isotope abundance. A mass balance on the M+7 mass isotopomer gives the following 
differential equation 
 
where C is the total glucose concentration in the extracellular medium, V is the liquid 
volume in each well (=175 μL), and N is the number of islets in each well. A mass balance 
on total glucose also gives the following equation 
 
Rearranging this equation to solve for 
𝑁
𝑉
 and substituting the result into Equation C.1 gives 
the following balance 
 
where we have used the relationship 𝑣𝑛𝑒𝑡 = 𝑣1 − 𝑣2 to simplify the result.  
𝑑(𝐶𝐴)
𝑑𝑡
= 𝐶
𝑑𝐴
𝑑𝑡
+ 𝐴
𝑑𝐶
𝑑𝑡
= −𝑣1𝐴
𝑁
𝑉
 (C.1) 
𝑑𝐶
𝑑𝑡
= −𝑣𝑛𝑒𝑡
𝑁
𝑉
 (C.2) 
𝐶
𝑑𝐴
𝑑𝑡
=
𝑣2
𝑣𝑛𝑒𝑡
𝐴
𝑑𝐶
𝑑𝑡
 (C.3) 
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In preliminary experiments in which islets were incubated with a doubly labeled 
[U-13C6; 1,2,3,4,5,6,6-
2H7]glucose tracer, we observed that a negligible amount of the 
M+13 tracer was completely de-deuterated to form M+6 glucose (data not shown). 
Therefore, in our experiments with the D7-glucose tracer, we assumed that none of the 
tracer was completely de-deuterated to form M+0 glucose and that the increase in M+1 
through M+6 fractional abundances must balance the decrease in M+7 fractional 
abundance over time. If we let B represent the sum of the M+1 through M+6 fractional 
abundances, this assumption implies that 
𝑑𝐵
𝑑𝑡
= −
𝑑𝐴
𝑑𝑡
, and therefore the sum A+B is 
constant. Dividing Equation C.3 by A+B gives the following result 
 
where A is the ratio 
𝐴
𝐴+𝐵
. In contrast to Equation C.3, this equation is normalized to remove 
the effects of the M+0 mass isotopomer abundance, an adjustment that was found to 
improve precision of the cycling calculation by removing variability associated with 
unintended carryover of unlabeled glucose from the preculture. Integrating Equation C.4 
with respect to time gives the final result 
 
where D is a constant of integration whose value depends on the initial enrichment and 
concentration of glucose in the culture medium. Therefore, the slope of the ln (𝐴′) versus 
ln (𝐶) plot can be used to estimate the cycling rate as a percentage of uptake v2/vnet.  
  
 
 𝐶
𝑑𝐴′
𝑑𝑡
=
𝑣2
𝑣𝑛𝑒𝑡
𝐴′
𝑑𝐶
𝑑𝑡
 (C.4) 
 
 ln(𝐴
′) =
𝑣2
𝑣𝑛𝑒𝑡
ln(𝐶) + 𝐷 (C.5) 
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APPENDIX D 
USER MANUAL FOR THE BATCH GUI 
Introduction 
inca_batch is a MATLAB-based graphical user interface (GUI) designed to batch data 
import, export, and fitting within the framework of the INCA environment (77). The GUI 
significantly reduces analysis time.  
 
Getting Started 
Extract the contents of the batch folder into the INCA directory. Open MATLAB and 
launch INCA. In the Current Folder window, right-click on the batch folder and add it to 
the path. Launch the batch GUI by typing inca_batch on the command line (Figure D.1).  
 
Figure D.1 
The initialized inca_batch GUI 
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Import Data 
1. Load a model from the Model menu (Model >> Load).  
a. The model should contain at least one experiment that can act as a template 
for additional experiments. The template experiment should define all of the 
metabolites of interest. 
b. Example: load mod_test.mat in batch/example1 (Figure D.2) 
 
Figure D.2 
The batch GUI with mod_test loaded. The box on the left-hand side displays the experiment 
names, while the box on the right-hand side displays a summary of the selected experiment. 
 
2. Organize MIDs for additional experiments in an Excel spreadsheet as in Figure D.3. 
a. The spreadsheet must be formatted as shown in the examples. Of note, the 
metabolite identifiers in the first column must exactly match the metabolite 
names defined in the INCA model.  
b. Example: see MIDs_test.xlsx in batch/example1 
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Figure D.3 
An Excel spreadsheet defines MIDs and measurement errors (SE) for each timepoint of each 
experiment.  
 
3. Press the Import button and select the *.xlsx file. Wait for the data to load. When 
prompted, save the updated model. After loading, the imported experiments will 
appear in the list (Figure D.4). 
a. Example: import MIDs from MIDs_test.xlsx in batch/example1 
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Figure D.4 
The batch GUI displays the imported experiments. 
 
Export Data 
1. Select all of the experiments for which exported data is desired. Highlight multiple 
experiments by holding the Ctrl key or using Ctrl + Shift.  
2. If MIDs should be corrected for natural abundance, ensure Export corrected data 
under the Options menu is checked (Figure D.5). 
3. Press the Export button. When prompted, select a path and filename for the *.csv 
file. 
a. The exported file will be formatted as shown in Figure D.3.  
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Fitting Data 
Options (Figure D.5) 
Export run set-up: When checked, exports a *.csv file 
that defines the settings for each fit run in the batch, 
including the samples, timepoints, and metabolites that 
were active, designated by a 1 or 0, during that run. 
See batch/example1/run_test_setup.csv.  
Fit each experiment: When checked, the GUI will fit 
each experiment separately. When unchecked, the GUI will fit all of the user-
selected experiments at the same time. 
Fit each timepoint: When checked, the GUI will fit each timepoint separately. When 
unchecked, the GUI will fit all of the user-selected timepoints at the same time.  
Select timepoints…: Allows the user to select specific timepoints. For example, allows 
for the exclusion of baseline samples.   
Fit options…: Allows the user to define the number of random starts and the 
confidence interval alpha value.  
Fitting Experiments to the Model 
1. Select the experiments to fit to the model. Hold down the Ctrl key to highlight 
multiple experiments.  
2. Set the desired fitting options as described above.  
3. Press the Run button (Figure D.4). When prompted, select a path and filename for 
the data.  
Figure D.5 
The Options menu defines 
the batch protocol for data 
fitting. 
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APPENDIX E 
DESCRIPTION OF MATHEMATICAL MODELING FOR FLUX ANALYSIS 
 
 The INCA software suite (77) mathematically describes the metabolic reaction 
network (Table A1) through a series of balance equations that define the relationship 
between fluxes and MIDs. A decomposition method is used to break isotopomers into 
elementary metabolite units (EMUs) to reduce computational burden (3). Each EMU 
includes a subset of metabolite atoms directly involved in atom transitions. EMUs are 
organized into size blocks, where size refers to the number of atoms represented in the 
EMU. INCA employs size decoupling of large blocks for efficiency (78); furthermore, 
EMUs and EMU balance equations are derived through automation. These features allow 
INCA users to build models of arbitrary complexity, test assumptions, and perform 
simulations with relative ease. The analysis presented in this study can be replicated by 
setting up the network (Table A1) in INCA or in other software platforms designed for 
MFA (58, 63, 64, 74, 76, 79). 
 The network detailed in Table A1 breaks down into 108 EMUs organized within 
13 EMU blocks. One EMU balance equation is derived for each block of the form: 
 
Ax + By = 0 (E.1) 
 
where A and B are functions of model fluxes and x and y are functions of EMU MIDs. 
EMU balance equations are detailed in S. Table 2. In these equations, the fluxes in matrices 
A and B are described in Table A1. The x and y matrices define the EMU by the metabolite 
name and the subset of atoms it includes. EMU atom numbering is based on the atomic 
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definitions for each metabolite from Table A1. For example, carbon and hydrogen atoms 
in Gluc.ext are defined as AaBbCcDdEeFfg in the VEndoRa model reaction, where capital 
letters refer to carbon atoms and lowercase letters refer to hydrogen atoms. The atoms are 
numbered sequentially for EMU definitions, where A=1, a=2, B=3, b=4, etc. There are six 
Gluc.ext EMUs (Table E.1) that correspond to the six measured glucose derivative 
fragments shown in Figure 2B. These EMUs are highlighted in bold in the EMU balance 
equations. 
 The relationships described in the EMU balance equations are logical. For example, 
the EMU balance equation for block 13 (Table E.2) shows that the mass isotopomer 
distribution for G6P (x, row 1) is dependent on the fluxes VGPI, VPYGL, and VEndoRa (A, 
column 1). Total glucose, Gluc.ext (x, row 2), is dependent on the [6,6-2H2]glucose infusion 
flux, Vinf, and endogenous glucose production, VEndoRa (A, column 2). The metabolites that 
form G6P and Gluc.ext EMUs, the input EMUs, are defined in y and include infused 
glucose (Gluc.inf), F6P, and Glycogen. These input EMUs feed through Vinf, VGPI, and 
VPYGL, respectively (B). The F6P input is shown as a convolution of a 12 atom F6P EMU 
MID and a hydrogen MID (F6P1∙3∙4∙5∙6∙7∙8∙9∙10∙11∙12∙13 x  H1; y, row 2). The F6P EMU does not 
include the second defined atom, a hydrogen, because it is lost in the conversion of F6P to 
G6P and replaced by a hydrogen (H1) from water. This hydrogen exchange is also 
represented in the convolution of a 12 atom glycogen EMU and a hydrogen MID 
(Glycogen1∙2∙3∙5∙6∙7∙8∙9∙10∙11∙12∙13 x  H1; y, row 3). Since the outputs (A * x) and inputs (B * y) 
must balance, their sum is equal to zero.  
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Table E.1 
Gluc.ext EMUs correspond to measured glucose fragments. 
 
Gluc.ext EMUs Fragment (m/z) 
Gluc.ext1∙2∙3∙4∙5∙6∙7∙8∙9∙10∙11∙12∙13 301 
Gluc.ext1∙3∙4∙5∙6∙7∙8∙9∙10 370 
Gluc.ext7∙8∙9∙10∙11∙12∙13 259 
Gluc.ext1∙3∙4∙5∙6∙7∙8 173 
Gluc.ext9∙10∙11∙12∙13 145 
Gluc.ext1∙2∙3∙4               284 
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Table E.2 
EMU Balance Equations. 
           Blo
ck
 1
3
 
B
lo
ck
 1
2
 
B
lo
ck
 1
1
 
B
lo
ck
 1
0
 
B
lo
ck
 9
 
B
lo
ck
 8
 
 120 
 
 
                                                                                                                                          
 
B
lo
ck
 7
 
 121 
 
   
B
lo
ck
 6
 
 122 
 
  
  
B
lo
ck
 5
 
 123 
 
  B
lo
ck
 4
 
 124 
 
  
B
lo
ck
 3
 
 125 
 
 
  
B
lo
ck
 2
 
 126 
 
   
  
B
lo
ck
 1
 
 127 
 
REFERENCES 
1. Antoniewicz MR, Kelleher JK, and Stephanopoulos G. Accurate assessment of 
amino acid mass isotopomer distributions for metabolic flux analysis. Analytical chemistry 
79: 7554-7559, 2007. 
2. Antoniewicz MR, Kelleher JK, and Stephanopoulos G. Determination of 
confidence intervals of metabolic fluxes estimated from stable isotope measurements. 
Metabolic engineering 8: 324-337, 2006. 
3. Antoniewicz MR, Kelleher JK, and Stephanopoulos G. Elementary metabolite 
units (EMU): a novel framework for modeling isotopic distributions. Metabolic 
engineering 9: 68-86, 2007. 
4. Antoniewicz MR, Kelleher JK, and Stephanopoulos G. Measuring deuterium 
enrichment of glucose hydrogen atoms by gas chromatography/mass spectrometry. 
Analytical chemistry 83: 3211-3216, 2011. 
5. Arden SD, Zahn T, Steegers S, Webb S, Bergman B, O'Brien RM, and Hutton 
JC. Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic 
subunit-related protein. Diabetes 48: 531-542, 1999. 
6. Ashcroft SJ, and Randle PJ. Glucose-6-phosphatase activity of mouse pancreatic 
islets. Nature 219: 857-858, 1968. 
7. Bentsi-Barnes K, Doyle ME, Abad D, and Kandeel F. Detailed protocol for 
evaluation of dynamic perifusion of human islets to assess β-cell function. Islets 2011. 
8. Berglund M, and Wieser ME. Isotopic compositions of the elements 2009 
(IUPAC Technical Report). Pure and Applied Chemistry 83: 397-410, 2011. 
9. Bouatia-Naji N, Bonnefond A, Baerenwald DA, Marchand M, Bugliani M, 
Marchetti P, Pattou F, Printz RL, Flemming BP, Umunakwe OC, Conley NL, 
Vaxillaire M, Lantieri O, Balkau B, Marre M, Levy-Marchal C, Elliott P, Jarvelin 
MR, Meyre D, Dina C, Oeser JK, Froguel P, and O'Brien RM. Genetic and functional 
assessment of the role of the rs13431652-A and rs573225-A alleles in the G6PC2 promoter 
that are strongly associated with elevated fasting glucose levels. Diabetes 59: 2662-2671, 
2010. 
10. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, 
Cavalcanti-Proenca C, Marchand M, Hartikainen AL, Sovio U, De Graeve F, Rung 
J, Vaxillaire M, Tichet J, Marre M, Balkau B, Weill J, Elliott P, Jarvelin MR, Meyre 
D, Polychronakos C, Dina C, Sladek R, and Froguel P. A polymorphism within the 
G6PC2 gene is associated with fasting plasma glucose levels. Science 320: 1085-1088, 
2008. 
11. Boustead JN, Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, and 
O'Brien RM. Identification and characterization of a cDNA and the gene encoding the 
 128 
 
mouse ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein. 
Journal of molecular endocrinology 32: 33-53, 2004. 
12. Boztug K, Appaswamy G, Ashikov A, Schaffer AA, Salzer U, Diestelhorst J, 
Germeshausen M, Brandes G, Lee-Gossler J, Noyan F, Gatzke AK, Minkov M, Greil 
J, Kratz C, Petropoulou T, Pellier I, Bellanne-Chantelot C, Rezaei N, Monkemoller 
K, Irani-Hakimeh N, Bakker H, Gerardy-Schahn R, Zeidler C, Grimbacher B, Welte 
K, and Klein C. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl 
J Med 360: 32-43, 2009. 
13. Burgess SC, He T, Yan Z, Lindner J, Sherry DA, Malloy CR, Browning JD, 
and Magnuson MA. Cytosolic phosphoenolpyruvate carboxykinase does not solely 
control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metabolism 5: 
313-320, 2007. 
14. Caprio S. Obesity and type 2 diabetes: the twin epidemic: preface. Diabetes 
Spectrum 16: 230-230, 2003. 
15. Chandramouli V, Khan A, Ostenson CG, Berggren PO, Low H, Landau BR, 
and Efendic SE. Quantification of glucose cycling and the extent of equilibration of 
glucose 6-phosphate with fructose 6-phosphate in islets from ob/ob mice. Biochem J 278 ( 
Pt 2): 353-359, 1991. 
16. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, Silver KD, Timpson 
NJ, Hansen T, Orru M, Grazia Piras M, Bonnycastle LL, Willer CJ, Lyssenko V, 
Shen H, Kuusisto J, Ebrahim S, Sestu N, Duren WL, Spada MC, Stringham HM, 
Scott LJ, Olla N, Swift AJ, Najjar S, Mitchell BD, Lawlor DA, Smith GD, Ben-Shlomo 
Y, Andersen G, Borch-Johnsen K, Jorgensen T, Saramies J, Valle TT, Buchanan TA, 
Shuldiner AR, Lakatta E, Bergman RN, Uda M, Tuomilehto J, Pedersen O, Cao A, 
Groop L, Mohlke KL, Laakso M, Schlessinger D, Collins FS, Altshuler D, Abecasis 
GR, Boehnke M, Scuteri A, and Watanabe RM. Variations in the G6PC2/ABCB11 
genomic region are associated with fasting glucose levels. J Clin Invest 118: 2620-2628, 
2008. 
17. Chen Z, and Zhong C. Decoding Alzheimer's disease from perturbed cerebral 
glucose metabolism: implications for diagnostic and therapeutic strategies. Progress in 
Neurobiology 108: 21-43, 2013. 
18. Cheung YY, Kim SY, Yiu WH, Pan CJ, Jun HS, Ruef RA, Lee EJ, Westphal 
H, Mansfield BC, and Chou JY. Impaired neutrophil activity and increased susceptibility 
to bacterial infection in mice lacking glucose-6-phosphatase-beta. J Clin Invest 117: 784-
793, 2007. 
19. Dadon D, Tornovsky-Babaey S, Furth-Lavi J, Ben-Zvi D, Ziv O, Schyr-Ben-
Haroush R, Stolovich-Rain M, Hija A, Porat S, Granot Z, Weinberg-Corem N, Dor 
Y, and Glaser B. Glucose metabolism: key endogenous regulator of beta-cell replication 
and survival. Diabetes Obes Metab 14 Suppl 3: 101-108, 2012. 
 129 
 
20. Easley C, Rocheleau J, Head W, and Piston D. Quantitative measurement of zinc 
secretion from pancreatic islets with high temporal resolution using droplet-based 
microfluidics. Analytical chemistry 81: 9086-9095, 2009. 
21. Egnatchik RA, Leamy AK, Jacobson DA, and Shiota M. ER calcium release 
promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate 
overload. Molecular Metabolism 3: 544–553, 2014. 
22. Egnatchik RA, Leamy AK, Noguchi Y, and Shiota M. Palmitate-induced 
activation of mitochondrial metabolism promotes oxidative stress and apoptosis in 
H4IIEC3 rat hepatocytes. Metabolism 63: 283-295, 2014. 
23. Fernandez C, Des Rosiers C, Previs S, David F, and Brunengraber H. 
Correction of 13C mass isotopomer distributions for natural stable isotope abundance. 
Journal of mass spectrometry : JMS 31: 255-262, 1996. 
24. Foster JD, Pederson BA, and Nordlie RC. Glucose-6-phosphatase structure, 
regulation, and function: an update. Proc Soc Exp Biol Med 215: 314-332, 1997. 
25. Groen AK, Roermund VCW, Vervoorn RC, and Tager JM. Control of 
gluconeogenesis in rat liver cells. Flux control coefficients of the enzymes in the 
gluconeogenic pathway in the absence and presence of glucagon. Biochem J 237: 379-389, 
1986. 
26. Han B, Serra P, Amrani A, Yamanouchi J, Maree AF, Edelstein-Keshet L, and 
Santamaria P. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high 
efficiency of a low-affinity peptide. Nat Med 11: 645-652, 2005. 
27. Hasenour CM, Wall ML, and Ridley DE. Mass Spectrometry-Based Microassay 
of 2H and 13C Plasma Glucose Labeling to Quantify Liver Metabolic Fluxes In vivo. 
American Journal of Physiology, Endocrinology and Metabolism 309: 191-203, 2015. 
28. Heiden VMG, Cantley LC, and Thompson CB. Understanding the Warburg 
effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009. 
29. Hutton JC, and O'Brien RM. The glucose-6-phosphatase catalytic subunit gene 
family. J Biol Chem 284: 29241-29245, 2009. 
30. Iynedjian PB. Molecular physiology of mammalian glucokinase. Cellular and 
molecular life sciences : CMLS 66: 27-42, 2009. 
31. Jarchum I, Nichol L, Trucco M, Santamaria P, and DiLorenzo TP. 
Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol 
127: 359-365, 2008. 
32. Jin ES, Beddow SA, Malloy CR, and Samuel VT. Hepatic glucose production 
pathways after three days of a high-fat diet. Metabolism 62: 152-162, 2013. 
 130 
 
33. Jin ES, Jones JG, Merritt M, Burgess SC, and Malloy CR. Glucose production, 
gluconeogenesis, and hepatic tricarboxylic acid cycle fluxes measured by nuclear magnetic 
resonance analysis of a single glucose derivative. Analytical Biochemistry 327: 149-155, 
2004. 
34. Jones JG, Solomon MA, Cole SM, Sherry AD, and Malloy CR. An integrated 
2H and 13C NMR study of gluconeogenesis and TCA cycle flux in humans. American 
Journal of Physiology-Endocrinology And Metabolism 281: 848-856, 2001. 
35. Kayton NS, Poffenberger G, and Henske J. Human islet preparations distributed 
for research exhibit a variety of insulin-secretory profiles. American Journal of Physiology, 
Endocrinology and Metabolism 308: 592-602, 2015. 
36. Khan A, Chandramouli V, Ostenson CG, Ahren B, Schumann WC, Low H, 
Landau BR, and Efendic S. Evidence for the presence of glucose cycling in pancreatic 
islets of the ob/ob mouse. J Biol Chem 264: 9732-9733, 1989. 
37. Khan A, Chandramouli V, Ostenson CG, Berggren PO, Low H, Landau BR, 
and Efendic S. Glucose Cycling Is Markedly Enhanced in Pancreatic-Islets of Obese 
Hyperglycemic Mice. Endocrinology 126: 2413-2416, 1990. 
38. Khan A, Chandramouli V, Ostenson CG, Low H, Landau BR, and Efendic S. 
Glucose cycling in islets from healthy and diabetic rats. Diabetes 39: 456-459, 1990. 
39. Khan A, and Efendic S. Evidence That Increased Glucose Cycling in Islets of 
Diabetic Ob/Ob Mice Is a Primary Feature of the Disease. Am J Physiol-Endoc M 269: 
E623-E626, 1995. 
40. Khan A, Narangoda S, Ahren B, Holm C, Sundler F, and Efendic S. Long-term 
leptin treatment of ob/ob mice improves glucose-induced insulin secretion. Int J Obes Relat 
Metab Disord 25: 816-821, 2001. 
41. Kim NH. Obstructive sleep apnea and abnormal glucose metabolism. Diabetes & 
metabolism journal 36: 268-272, 2012. 
42. Kooi BT, Onuma H, Oeser JK, Svitek CA, Allen SR, Kooi CW, Chazin WJ, 
and O’Brien RM. The glucose-6-phosphatase catalytic subunit gene promoter contains 
both positive and negative glucocorticoid response elements. Molecular Endocrinology 19: 
3001-3022, 2005. 
43. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, and 
Kalhan SC. Contributions of gluconeogenesis to glucose production in the fasted state. 
The Journal of clinical investigation 98: 378-385, 1996. 
44. Laybutt DR, Glandt M, Xu G, Ahn YB, Trivedi N, Bonner-Weir S, and Weir 
GC. Critical reduction in beta-cell mass results in two distinct outcomes over time. 
Adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem 278: 
2997-3005, 2003. 
 131 
 
45. Leamy AK, Egnatchik RA, and Young JD. Molecular mechanisms and the role 
of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Progress in 
lipid research 52: 165-174, 2013. 
46. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, 
Serreze DV, Shabanowitz J, Hunt DF, Nathenson SG, Santamaria P, and DiLorenzo 
TP. Identification of the beta cell antigen targeted by a prevalent population of pathogenic 
CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A 100: 8384-8388, 2003. 
47. Malaisse W, Malaisse-Lagae F, Liemans V, Ottinger R, and Willem R. 
Phosphoglucoisomerase-catalyzed interconversion of hexose phosphates: isotopic 
discrimination between hydrogen and deuterium. Molecular and cellular biochemistry 93: 
153-165, 1990. 
48. Martin CC, Bischof LJ, Bergman B, Hornbuckle LA, Hilliker C, Frigeri C, 
Wahl D, Svitek CA, Wong R, Goldman JK, Oeser JK, Lepretre F, Froguel P, O'Brien 
RM, and Hutton JC. Cloning and characterization of the human and rat islet-specific 
glucose-6-phosphatase catalytic subunit-related protein (IGRP) genes. J Biol Chem 276: 
25197-25207, 2001. 
49. Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, and O'Brien RM. 
Identification and Characterization of a Human cDNA and Gene Encoding a Ubiquitously 
Expressed Glucose-6-Phosphatase Catalytic Subunit-Related Protein. Journal of molecular 
endocrinology 29: 205-222, 2002. 
50. Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired 
by the glucokinase glucose sensor paradigm. Diabetes 45: 223-241, 1996. 
51. Mithieux G. New knowledge regarding glucose-6 phosphatase gene and protein 
and their roles in the regulation of glucose metabolism. Eur J Endocrinol 136: 137-145, 
1997. 
52. Mukherjee R, Wagar D, Stephens TA, Lee-Chan E, and Singh B. Identification 
of CD4+ T cell-specific epitopes of islet-specific glucose-6-phosphatase catalytic subunit-
related protein: a novel beta cell autoantigen in type 1 diabetes. J Immunol 174: 5306-5315, 
2005. 
53. Murphy TA, Dang CV, and Young JD. Isotopically nonstationary 13C flux 
analysis of Myc-induced metabolic reprogramming in B-cells. Metabolic engineering 15: 
206-217, 2012. 
54. O'Brien RM. Moving on from GWAS: functional studies on the G6PC2 gene 
implicated in the regulation of fasting blood glucose. Current diabetes reports 13: 768-
777, 2013. 
55. Perales MA, Sener A, and Malaisse WJ. Hexose metabolism in pancreatic islets: 
the glucose-6-phosphatase riddle. Mol Cell Biochem 101: 67-71, 1991. 
 132 
 
56. Petrolonis A, Yang Q, Tummino P, Fish S, Prack A, Jain S, Parsons T, Li P, 
Dales N, Ge L, Langston S, Schuller A, An W, Tartaglia L, Chen H, and Hong S-B. 
Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related 
protein (IGRP). The Journal of biological chemistry 279: 13976-13983, 2004. 
57. Pound LD, Oeser JK, O'Brien TP, Wang Y, Faulman CJ, Dadi PK, Jacobson 
DA, Hutton JC, McGuinness OP, Shiota M, and O'Brien RM. G6PC2: a negative 
regulator of basal glucose-stimulated insulin secretion. Diabetes 62: 1547-1556, 2013. 
58. Quek L-EE, Wittmann C, Nielsen LK, and Krömer JO. OpenFLUX: efficient 
modelling software for 13C-based metabolic flux analysis. Microbial cell factories 8: 25, 
2008. 
59. Rocheleau J, Walker G, Head W, McGuinness O, and Piston D. Microfluidic 
glucose stimulation reveals limited coordination of intracellular Ca2+ activity oscillations 
in pancreatic islets. Proceedings of the National Academy of Sciences of the United States 
of America 101: 12899-12903, 2004. 
60. Rowe I, Chiaravalli M, Mannella V, Ulisse V, and Quilici G. Defective glucose 
metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nature 
medicine 19: 488-493, 2013. 
61. Satapati S, Sunny NE, Kucejova B, Fu X, He TT, Méndez-Lucas A, Shelton 
JM, Perales JC, Browning JD, and Burgess SC. Elevated TCA cycle function in the 
pathology of diet-induced hepatic insulin resistance and fatty liver. Journal of lipid 
research 53: 1080-1092, 2012. 
62. Small GW, Ercoli LM, and Silverman DHS. Cerebral metabolic and cognitive 
decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97: 
6037-6042, 2000. 
63. Sokol S, Millard P, and Portais JC. influx_s: increasing numerical stability and 
precision for metabolic flux analysis in isotope labelling experiments. Bioinformatics 28: 
687-93, 2012. 
64. Srour O, Young JD, and Eldar YC. Fluxomers: a new approach for 13C 
metabolic flux analysis. BMC systems biology 5: 129, 2010. 
65. Sunny NE, Parks EJ, Browning JD, and Burgess SC. Excessive hepatic 
mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver 
disease. Cell metabolism 14: 804-810, 2011. 
66. Sweet IR, Najafi H, Li G, Grodberg J, and Matschinsky FM. Measurement and 
modeling of glucose-6-phosphatase in pancreatic islets. Am J Physiol 272: E696-711, 1997. 
67. Templeton N, Lewis A, Dorai H, Qian EA, Campbell MP, Smith KD, Lang SE, 
Betenbaugh MJ, and Young JD. The impact of anti-apoptotic gene Bcl-2 expression on 
CHO central metabolism. Metabolic engineering 25: 92-102, 2014. 
 133 
 
68. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, 
Polonsky KS, and Bell GI. Evolution of beta-cell dysfunction in the male Zucker diabetic 
fatty rat. Diabetes 44: 1447-1457, 1995. 
69. van de Werve G, Lange A, Newgard C, Mechin MC, Li Y, and Berteloot A. 
New lessons in the regulation of glucose metabolism taught by the glucose 6-phosphatase 
system. Eur J Biochem 267: 1533-1549, 2000. 
70. Van Schaftingen E, and Gerin I. The glucose-6-phosphatase system. Biochem J 
362: 513-532, 2002. 
71. Wall ML, Pound LD, Trenary I, and O'Brien RM. Novel Stable Isotope 
Analyses Demonstrate Significant Rates of Glucose Cycling in Mouse Pancreatic Islets. 
Diabetes 64: 2129-2137, 2015. 
72. Wang Y, Martin CC, Oeser JK, Sarkar S, McGuinness OP, Hutton JC, and 
O'Brien RM. Deletion of the Gene Encoding the Islet-Specific Glucose-6-Phosphatase 
Catalytic Subunit-Related Protein Autoantigen Results in a Mild Metabolic Phenotype. 
Diabetologia 50: 774-778, 2007. 
73. Wegner A, Weindl D, ger C, Sapcariu SC, Dong X, Stephanopoulos G, and 
Hiller K. Fragment formula calculator (FFC): determination of chemical formulas for 
fragment ions in mass spectrometric data. Analytical chemistry 86: 2221-2228, 2014. 
74. Weitzel M, Nöh K, Dalman T, Niedenführ S, Stute B, and Wiechert W. 
13CFLUX2—high-performance software suite for 13C-metabolic flux analysis. 
Bioinformatics 29: 143-145, 2013. 
75. Yang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum C, 
Pihoker C, James EA, and Kwok WW. Islet-specific glucose-6-phosphatase catalytic 
subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol 176: 2781-
2789, 2006. 
76. Yoo H, Antoniewicz MR, and Stephanopoulos G. Quantifying reductive 
carboxylation flux of glutamine to lipid in a brown adipocyte cell line. The Journal of 
biological chemistry 283: 20621-20627, 2008. 
77. Young JD. INCA: a computational platform for isotopically non-stationary 
metabolic flux analysis. Bioinformatics (Oxford, England) 30: 1333-1335, 2014. 
78. Young JD, Walther JL, Antoniewicz MR, Yoo H, and Stephanopoulos G. An 
elementary metabolite unit (EMU) based method of isotopically nonstationary flux 
analysis. Biotechnology and Bioengineering 99: 686-699, 2008. 
79. Zamboni N, Fischer E, and Sauer U. FiatFlux--a software for metabolic flux 
analysis from 13C-glucose experiments. BMC bioinformatics 6: 209, 2004. 
 134 
 
80. Zhang H, Stevens RD, Young SP, and Surwit R. A Convenient LC-MS Method 
for Assessment of Glucose Kinetics In Vivo with d-[13C6] Glucose as a Tracer. Clinical 
chemistry 55: 527-532, 2009. 
 
 
